

GenCore version 5.1.6
Copyright (C) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 13:18:37 ; Search time 2544 Seconds
(without alignments)
557.662 Million cell updates/sec

Title: US-09-890-363-1
Perfect score: 30
Sequence: 1 gtaattgcgcgaagaagaattgtttctgtc 30

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 2024102

Minimum DB seq length: 0
Maximum DB seq length: 75

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl:
1: gb_da.*
2: gb_htg.*
3: gb_in.*
4: gb_on.*
5: gb_ov.*
6: gb_pat.*
7: gb_ph.*
8: gb_pl.*
9: gb_pr.*
10: gb_ro.*
11: gb_sts.*
12: gb_sy.*
13: gb_un.*
14: gb_vi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	30	100.0	30	6	BD237979 Formulati
2	30	100.0	30	6	AX032823 Sequence
3	26.8	89.3	30	6	BD237980 Formulati
4	26.8	89.3	30	6	BD237985 Formulati
5	26.8	89.3	30	6	BD237989 Formulati
6	26.8	89.3	30	6	AX032824 Sequence
7	26.8	89.3	30	6	AX032829 Sequence
8	26.8	89.3	30	6	AX032833 Sequence
9	17.2	57.3	30	6	BD237986 Formulati
10	17.2	57.3	30	6	AX032830 Sequence
11	17	56.7	43	6	AR411028 Sequence
12	16.8	56.0	65	11	BX547960 Arabidops
13	16.8	55.3	50	6	AX952037 Sequence
14	16.6	55.3	50	6	AX952631 Sequence
15	16.2	54.0	49	6	AX952011 Sequence
16	16.2	54.0	49	6	AX952044 Sequence
17	16.2	54.0	49	6	AX952605 Sequence
18	16.2	54.0	49	6	AX952638 Sequence
19	16.2	54.0	60	6	CQ538369 Sequence

20	16.2	54.0	70	6	E15744	E15744 DNA encodin
21	15.8	52.7	41	6	AR109135	AR109135 Sequence
22	15.8	52.7	41	6	AR200790	AR200790 Sequence
23	15.8	52.7	47	6	AR284458	AR284458 Sequence
24	15.4	51.3	43	6	AX484469	AX484469 Sequence
25	15.4	51.3	51	6	CQ007362	CQ007362 Sequence
26	15.4	51.3	65	6	CQ560587	CQ560587 Sequence
27	15.2	50.7	40	6	AX774088	AX774088 Sequence
28	15	50.0	41	6	AX515819	AX515819 Sequence
29	15	50.0	41	6	AX518414	AX518414 Sequence
30	15	50.0	50	6	AX952015	AX952015 Sequence
31	15	50.0	50	6	AX952045	AX952045 Sequence
32	15	50.0	50	6	AX952063	AX952063 Sequence
33	15	50.0	50	6	AX952609	AX952609 Sequence
34	15	50.0	50	6	AX952639	AX952639 Sequence
35	15	50.0	50	6	AX952657	AX952657 Sequence
36	15	50.0	60	6	CQ831872	CQ831872 Sequence
37	14.8	49.3	35	6	E16238	E16238 PCR primer
38	14.8	49.3	35	6	E16283	E16283 PCR primer
39	14.8	49.3	35	6	AX128301	AX128301 Sequence
40	14.8	49.3	36	3	AF251753S5	AF251757 Japyx sp.
41	14.8	49.3	43	6	AX484455	AX484455 Sequence
42	14.8	49.3	47	6	AR284544	AR284544 Sequence
43	14.8	49.3	59	6	AX684244	AX684244 Sequence
44	14.8	49.3	65	6	CQ531914	CQ531914 Sequence
45	14.8	49.3	65	6	CQ531944	CQ531944 Sequence

ALIGNMENTS

RESULT 1
BD237979
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD237979 30 bp DNA linear PAT 17-JUL-2003
Formulations comprising antisense nucleotides to connexins.
BD237979
BD237979.1 GI:33047749
JP 2002535377-A/1.
synthetic construct
artificial sequences.
1 (bases 1 to 30)
Becker,D.L. and Green,C.R.
Formulations comprising antisense nucleotides to connexins
Patent: JP 2002535377-A 1 22-OCT-2002;
UNIVERSITY COLLEGE LONDON
OS Artificial Sequence
PN JP 2002535377-A/1
PD 22-OCT-2002
PF 27-JAN-2000 JP 2000595711
PR 27-JAN-1999 NZ 333928 07-OCT-1999 NZ 500190 PI
DAVID LAURENCE BECKER,COLIN RICHARD GREEN
PC A61K31/711,A61K9/06,A61K9/10,A61K47/16,A61K47/34,A61K47/46, PC
A61K48/00,
PC A61P17/02,A61P17/12,A61P17/16,A61P25/00,A61P29/00,A61P43/00,
PC A61P43/00//
PC C12N15/09,C12N15/00
CC Description of Artificial Sequence: Oligonucleotide FH Key
Location/Qualifiers
FT source
FT 1..30
Location/Qualifiers
1..30
/organism='Artificial Sequence',
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

ORIGIN
Query Match 100.0%; Score 30; DB 6; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTAATTGGCGCAAGAGAAATTGTTCTGTC 30

```

Db      1  GTAATTCGGCAGAGAAATTGTTCTGTC 30
|||||
RESULT 2
AX032823      30 bp      DNA      linear      PAT 21-SEP-2000
LOCUS
DEFINITION   Formulations comprising antisense nucleotides to connexins
ACCESSION   AX032823
VERSION      AX032823.1 GI:10279797
KEYWORDS     synthetic construct
SOURCE       synthetic construct
ORGANISM     artificial sequences.
REFERENCE    1
AUTHORS      Becker, D.L. and Green, C.R.
TITLE        Formulations comprising antisense nucleotides to connexins
JOURNAL      Patent: WO 0044409-A 1 03-AUG-2000;
              BECKER DAVID LAURENCE (GB) ; UNIV LONDON (GB) ; GREEN COLIN RICHARD
              (NZ)
FEATURES     Location/Qualifiers
             1..30
             /organism="synthetic construct"
             /mol_type="unassigned DNA"
             /db_xref="taxon:32630"
             /note="Oligonucleotide"
ORIGIN
Query Match      100.0%; Score 30; DB 6; Length 30;
Best Local Similarity 100.0%; Pred.No. 0.014;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  GTAATTCGGCAGAGAAATTGTTCTGTC 30
|||||
Db      1  GTAATTCGGCAGAGAAATTGTTCTGTC 30
|||||

RESULT 3
BD237980      30 bp      DNA      linear      PAT 17-JUL-2003
LOCUS
DEFINITION   Formulations comprising antisense nucleotides to connexins.
ACCESSION   BD237980
VERSION      BD237980.1 GI:33047750
KEYWORDS     JP 2002535377-A/2.
SOURCE       synthetic construct
ORGANISM     artificial sequences.
REFERENCE    1 (bases 1 to 30)
AUTHORS      Becker, D.L. and Green, C.R.
TITLE        Formulations comprising antisense nucleotides to connexins
JOURNAL      Patent: JP 2002535377-A 2 22-OCT-2002;
              UNIVERSITY COLLEGE LONDON
              OS Artificial Sequence
              PN JP 2002535377-A/2
              PD 22-OCT-2002
              PF 27-JAN-2000 JP 2000595711
              PR 27-JAN-1999 NZ 333928,07-OCT-1999 NZ 500190 PI
              PC A61K31/711,A61K9/06,A61K9/10,A61K47/16,A61K47/34,A61K47/46, PC
              A61K48/00,
              PC A61P17/02,A61P17/12,A61P17/16,A61P25/00,A61P29/00,A61P43/00,
              PC A61P43/00//
              CC Description of Artificial Sequence: Oligonucleotide FH Key
              Location/Qualifiers
              1..30
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"
ORIGIN

Query Match      89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred.No. 0.39;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1  GTAATTCGGCAGAGAAATTGTTCTGTC 30
|||||
Db      30  GTAATTCGGCAGAGAAATTGTTCTGTC 1
|||||

RESULT 5
BD237989/c
LOCUS
DEFINITION   Formulations comprising antisense nucleotides to connexins
ACCESSION   BD237989
VERSION      BD237989.1 GI:33047759
KEYWORDS     JP 2002535377-A/11.
SOURCE       synthetic construct
ORGANISM     artificial sequences.
REFERENCE    1 (bases 1 to 30)
AUTHORS      Becker, D.L. and Green, C.R.
TITLE        Formulations comprising antisense nucleotides to connexins
JOURNAL      Patent: JP 2002535377-A 11 22-OCT-2002;
              UNIVERSITY COLLEGE LONDON
              OS Artificial Sequence
              PN JP 2002535377-A/11
              COMMENT

```

```

Query Match      89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred.No. 0.39;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1  GTAATTCGGCAGAGAAATTGTTCTGTC 30
|||||
Db      1  GTAATTCGGCAGAGAAATTGTTCTGTC 30
|||||

RESULT 4
BD237985/c
LOCUS
DEFINITION   Formulations comprising antisense nucleotides to connexins.
ACCESSION   BD237985
VERSION      BD237985.1 GI:33047755
KEYWORDS     JP 2002535377-A/7.
SOURCE       synthetic construct
ORGANISM     synthetic construct
              artificial sequences.
REFERENCE    1 (bases 1 to 30)
AUTHORS      Becker, D.L. and Green, C.R.
TITLE        Formulations comprising antisense nucleotides to connexins
JOURNAL      Patent: JP 2002535377-A 7 22-OCT-2002;
              UNIVERSITY COLLEGE LONDON
              OS Artificial Sequence
              PN JP 2002535377-A/7
              PD 22-OCT-2002
              PF 27-JAN-2000 JP 2000595711
              PR 27-JAN-1999 NZ 333928,07-OCT-1999 NZ 500190 PI
              PC A61K31/711,A61K9/06,A61K9/10,A61K47/16,A61K47/34,A61K47/46, PC
              A61K48/00,
              PC A61P17/02,A61P17/12,A61P17/16,A61P25/00,A61P29/00,A61P43/00,
              PC A61P43/00//
              CC Description of Artificial Sequence: Oligonucleotide FH Key
              Location/Qualifiers
              1..30
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"
ORIGIN

Query Match      89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred.No. 0.39;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1  GTAATTCGGCAGAGAAATTGTTCTGTC 30
|||||
Db      30  GTAATTCGGCAGAGAAATTGTTCTGTC 1
|||||

RESULT 5
BD237989/c
LOCUS
DEFINITION   Formulations comprising antisense nucleotides to connexins
ACCESSION   BD237989
VERSION      BD237989.1 GI:33047759
KEYWORDS     JP 2002535377-A/11.
SOURCE       synthetic construct
ORGANISM     artificial sequences.
REFERENCE    1 (bases 1 to 30)
AUTHORS      Becker, D.L. and Green, C.R.
TITLE        Formulations comprising antisense nucleotides to connexins
JOURNAL      Patent: JP 2002535377-A 11 22-OCT-2002;
              UNIVERSITY COLLEGE LONDON
              OS Artificial Sequence
              PN JP 2002535377-A/11
              COMMENT

```

PD 22-OCT-2002
PF 27-JAN-2000 JP 2000595711
PR 27-JAN-1999 NZ 333928,07-OCT-1999 NZ 500190 PI
DAVID LAURENCE BECKER, COLIN RICHARD GREEN
PC A61K31/711, A61K9/06, A61K9/10, A61K47/16, A61K47/34, A61K47/46, PC
A61K48/00,
PC A61P17/02, A61P17/12, A61P17/16, A61P25/00, A61P29/00, A61P43/00,
PC A61P43/00//
PC C12N15/09, C12N15/00
CC Description of Artificial Sequence: Oligonucleotide FH Key
Location/Qualifiers
FT source 1.30
FT /organism='Artificial Sequence'.
FEATURES
source
1.30
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
ORIGIN
Query Match 89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39; 2; Indels 0; Gaps 0;
Matches 28; Conservative 0; Mismatches 0;
QY 1 GTAATTGGCGCAAGAAGAAATTGTTCTGTC 30
DB 30 GTAATTGGCGCAGGAGGAATTGTTCTGTC 1
RESULT 6
AX032824
LOCUS 30 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 2 from Patent WO0044409.
ACCESSION AX032824
VERSION AX032824.1 GI:10279798
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Becker, D.L. and Green, C.R.
TITLE Formulations comprising antisense nucleotides to connexins
JOURNAL Patent: WO 0044409-A 2 03-AUG-2000;
BECKER DAVID LAURENCE (GB); UNIV LONDON (GB); GREEN COLIN RICHARD (NZ)
FEATURES
source
1.30
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"
ORIGIN
Query Match 89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39; 2; Indels 0; Gaps 0;
Matches 28; Conservative 0; Mismatches 0;
QY 1 GTAATTGGCGCAAGAAGAAATTGTTCTGTC 30
DB 1 GTAATTGGCGCAGGAGGAATTGTTCTGTC 30
RESULT 7
AX032829/c
LOCUS 30 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 7 from Patent WO0044409.
ACCESSION AX032829
VERSION AX032829.1 GI:10279803
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1

AUTHORS
Becker, D.L. and Green, C.R.
TITLE Formulations comprising antisense nucleotides to connexins
JOURNAL Patent: WO 0044409-A 7 03-AUG-2000;
BECKER DAVID LAURENCE (GB); UNIV LONDON (GB); GREEN COLIN RICHARD (NZ)
FEATURES
source
1.30
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"
ORIGIN
Query Match 89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39; 2; Indels 0; Gaps 0;
Matches 28; Conservative 0; Mismatches 2;
QY 1 GTAATTGGCGCAAGAAGAAATTGTTCTGTC 30
DB 30 GTAATTGGCGCAGGAGGAATTGTTCTGTC 1
RESULT 8
AX032833/c
LOCUS 30 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 11 from Patent WO0044409.
ACCESSION AX032833
VERSION AX032833.1 GI:10279807
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Becker, D.L. and Green, C.R.
TITLE Formulations comprising antisense nucleotides to connexins
JOURNAL Patent: WO 0044409-A 11 03-AUG-2000;
BECKER DAVID LAURENCE (GB); UNIV LONDON (GB); GREEN COLIN RICHARD (NZ)
FEATURES
source
1.30
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"
ORIGIN
Query Match 89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39; 2; Indels 0; Gaps 0;
Matches 28; Conservative 0; Mismatches 2;
QY 1 GTAATTGGCGCAAGAAGAAATTGTTCTGTC 30
DB 30 GTAATTGGCGCAGGAGGAATTGTTCTGTC 1
RESULT 9
BD237986
LOCUS 30 bp DNA linear PAT 17-JUL-2003
DEFINITION Formulations comprising antisense nucleotides to connexins.
ACCESSION BD237986
VERSION BD237986.1 GI:33047756
KEYWORDS JP 2002535377-A/8.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 30)
AUTHORS Becker, D.L. and Green, C.R.
TITLE Formulations comprising antisense nucleotides to connexins
JOURNAL Patent: JP 2002535377-A 8 22-OCT-2002;
UNIVERSITY COLLEGE LONDON
COMMENT OS Artificial Sequence
PN JP 2002535377-A/8
PD 22-OCT-2002

PF 27-JAN-2000 JP 2000595711
 PR 27-JAN-1999 NZ 333928, 07-OCT-1999 NZ 500190 P1
 DAVID LAURENCE BECKER, COLIN RICHARD GREEN
 PC A61K31/711, A61K9/06, A61K9/10, A61K47/16, A61K47/34, A61K47/46, PC
 A61K48/00,
 PC A61P17/02, A61P17/12, A61P17/16, A61P25/00, A61P29/00, A61P43/00,
 PC A61P43/00//
 PC C12N15/09, C12N15/00
 CC Description of Artificial Sequence: Oligonucleotide FH Key
 Location/Qualifiers
 FT source 1..30
 FT /organism='Artificial Sequence'.
 FT Location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

ORIGIN
 Query Match 57.3%; Score 17.2; DB 6; Length 30;
 Best Local Similarity 73.3%; Pred. No. 8e+03; Indels 0; Gaps 0;
 Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Cy 1 GTAATTGGCGCAAGAGAAATTGTTCTGTC 30
 Db 1 GTAGTTACGACAGGAGGAATTGTTCTGTC 30

RESULT 10
 AX032830
 LOCUS 30 bp DNA linear PAT 21-SEP-2000
 DEFINITION Sequence 8 from Patent WO0044409.
 ACCESSION AX032830
 VERSION AX032830.1 GI:10279804
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM artificial sequences.

REFERENCE 1
 AUTHORS Becker, D.L. and Green, C.R.
 TITLE Formulations comprising antisense nucleotides to connexins
 JOURNAL Patent: WO 0044409-A 8 03-AUG-2000;
 BECKER DAVID LAURENCE (GB); UNIV LONDON (GB); GREEN COLIN RICHARD (NZ)

FEATURES
 source 1..30
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Oligonucleotide"

ORIGIN
 Query Match 57.3%; Score 17.2; DB 6; Length 30;
 Best Local Similarity 73.3%; Pred. No. 8e+03; Indels 0; Gaps 0;
 Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Cy 1 GTAATTGGCGCAAGAGAAATTGTTCTGTC 30
 Db 1 GTAGTTACGACAGGAGGAATTGTTCTGTC 30

RESULT 11
 AR411028/c
 LOCUS 43 bp DNA linear PAT 18-DEC-2003
 DEFINITION Sequence 17 from patent US 6635475.
 ACCESSION AR411028
 VERSION AR411028.1 GI:40162606
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 43)
 AUTHORS Helmann, J.D.

TITLE Bacillus subtilis extracytoplasmic function .sigma. factor
 JOURNAL Patent: US 6635475-A 17 21-OCT-2003;
 FEATURES
 source 1..43
 Location/Qualifiers
 /organism="unknown"
 /mol_type="genomic DNA"

ORIGIN
 Query Match 56.7%; Score 17; DB 6; Length 43;
 Best Local Similarity 80.0%; Pred. No. 1e+04; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Cy 2 TAATTGGCGCAAGAGAAATTGTTTC 26
 Db 31 TACGTGCAAGAAAGAAATGTTTC 7

RESULT 12
 BX547960
 LOCUS 65 bp DNA linear STS 02-JUL-2003
 DEFINITION Arabidopsis thaliana transposon insertion STS SM_3.39244, sequence tagged site.
 ACCESSION BX547960
 VERSION BX547960.1 GI:32440780
 KEYWORDS STS; STS, sequence tagged site.
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

REFERENCE 1
 AUTHORS Clarke, J.H., Bowles, B., Carter, J., Hart, D., McCullagh, B., Walsh, S., Langham, S., LeGrys, C., Jones, J.D.G. and Bevan, M.
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 65)
 AUTHORS Clarke, J.H.
 TITLE Direct Submission
 JOURNAL Submitted (02-JUL-2003) Clarke J.H., John Innes Centre, Colney Lane, Norwich, NR4 7UJ, UK

COMMENT AT denotes an activation tag dissociation transposon within a single line. ET an enhancer trap dissociation transposon, GT a gene trap dissociation transposon, MT a mis-expression enhancer trap dissociation transposon, SM a defective suppressor mutator dissociation transposon, _3 denotes a sequence derived from the 3' end of the transposon, _5 denotes a sequence derived from the 5' end of the transposon, BBSRC GARNET, ATIS project
 On-line seed stock requests: http://nasc.nott.ac.uk/ NASC stock code: N125955.

FEATURES
 source 1..65
 Location/Qualifiers
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /variety="Columbia-0 NASC stock code N1092"
 /db_xref="taxon:3702"
 /clone="AC022520"
 /note="Derived from superpool 17.29 NASC code N40772"

STS 1..65
 /standard_name="SM_3.39244"

ORIGIN
 Query Match 56.0%; Score 16.8; DB 11; Length 65;
 Best Local Similarity 90.0%; Pred. No. 1.3e+04; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 4 ATTGGCGCAAGAGAAATGT 23
 Db 19 ATTGCTGACAGACATGT 38

RESULT 13
 AX952037/c
 LOCUS 50 bp RNA linear PAT 08-JAN-2004
 DEFINITION Sequence 94 from Patent WO03093504.

ACCESSION AX952037
VERSION AX952037.1 GI:40782419
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Vater,A., Jarosch,F., Wettich,A. and Klussmann,S.
TITLE Method for amplifying nucleic acids
JOURNAL Patent: WO 03093504-A 94 13-NOV-2003;
Noxxon Pharma AG (DE)
FEATURES
source Location/Qualifiers
1..50
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
ORIGIN
Query Match 55.3%; Score 16.6; DB 6; Length 50;
Best Local Similarity 82.6%; Pred. No. 1.5e+04;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 8 CGGCAAGAGAGAAATGTTCTGTC 30
Db 36 CGTCAGACGAAATCGTTCTTTC 14
RESULT 14
AX952631/c
LOCUS AX952631 50 bp RNA linear PAT 08-JAN-2004
DEFINITION Sequence 186 from Patent WO03093472.
ACCESSION AX952631
VERSION AX952631.1 GI:40782971
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Vater,A., Maasch,C., Jarosch,F., Bell,M., Helmling,S.,
Bechtaeller,B., Moyroud,S., Stark,S., Klussmann,S., Ruppert,T.,
Schliene,K., Bahrenberg,G. and Gillen,C.
TITLE Cgrp binding nucleic acids
JOURNAL Patent: WO 03093472-A 186 13-NOV-2003;
Gruenenthal GmbH (DE) ; Noxxon Pharma AG (DE)
FEATURES
source Location/Qualifiers
1..50
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="CGRP-binding nucleic acid"
ORIGIN
Query Match 55.3%; Score 16.6; DB 6; Length 50;
Best Local Similarity 82.6%; Pred. No. 1.5e+04;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 8 CGGCAAGAGAGAAATGTTCTGTC 30
Db 36 CGTCAGACGAAATCGTTCTTTC 14
RESULT 15
AX952011/c
LOCUS AX952011 49 bp RNA linear PAT 08-JAN-2004
DEFINITION Sequence 68 from Patent WO03093504.
ACCESSION AX952011
VERSION AX952011.1 GI:40782393
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Vater,A., Jarosch,F., Wettich,A. and Klussmann,S.

TITLE Method for amplifying nucleic acids
JOURNAL Patent: WO 03093504-A 68 13-NOV-2003;
Noxxon Pharma AG (DE)
FEATURES
source Location/Qualifiers
1..49
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
ORIGIN
Query Match 54.0%; Score 16.2; DB 6; Length 49;
Best Local Similarity 72.4%; Pred. No. 2.3e+04;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY 2 TAATTGCGGCAAGAGAAATGTTCTGTC 30
Db 42 TCATCGTCACAAGACGAATCGTTCTTTC 14
Search completed: November 5, 2004, 16:35:12
Job time : 2550 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 13:14:14 ; Search time 343 Seconds
(without alignments)
459.133 Million cell updates/sec

Title: US-09-890-363-1
Perfect score: 30
Sequence: 1 gtaattgcggcagaagaattgtttctgtc 30

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 4224226

Minimum DB seq length: 0
Maximum DB seq length: 75

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_23Sep04:*

- 1: Geneseq1980s:*
- 2: Geneseq1990s:*
- 3: Geneseq2000s:*
- 4: Geneseq2001as:*
- 5: Geneseq2001bs:*
- 6: Geneseq2002as:*
- 7: Geneseq2002bs:*
- 8: Geneseq2003as:*
- 9: Geneseq2003bs:*
- 10: Geneseq2003cs:*
- 11: Geneseq2003ds:*
- 12: Geneseq2004s:*

* Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	30	100.0	30	3	AAA71646 Connexin
2	26.8	89.3	30	3	AAA71647 Connexin
3	26.8	89.3	30	3	AAA71652 Connexin
4	17.2	57.3	30	3	AAA71653 Chickens c
5	17	56.7	43	10	Adf50888 Bacillus
6	16.6	55.3	50	11	Adm73609 CGRP-bind
7	16.6	55.3	50	11	Adm68129 Oligonuc
8	16.6	55.3	50	11	Adm68129 Oligonuc
9	16.2	54.0	49	11	Adm73616 CGRP-bind
10	16.2	54.0	49	11	Adm73583 CGRP-bind
11	16.2	54.0	49	11	Adm67858 Rat alpha
12	16.2	54.0	49	11	Adm68137 Oligonuc
13	16.2	54.0	49	11	Adm68170 Oligonuc
14	16.2	54.0	49	11	Adm68130 Oligonuc
15	16.2	54.0	49	11	Adm67825 Rat alpha
16	16.2	54.0	60	6	ABN35256 Human spl
17	16.2	54.0	70	2	AAV23259 Synthetic
18	15.8	52.7	27	3	AAZ87224 Pinctada
19	15.8	52.7	41	2	AAV50625 Brassica
20	15.8	52.7	41	6	ABL96067 Brassica
21	15.6	52.0	24	6	ABL41518 Primer #2

22	15.4	51.3	43	6	ABZ27822	Candida e
23	15.4	51.3	51	4	AAAL32794	Human SNP
24	15.4	51.3	65	6	ABN57474	Mouse spl
25	15.2	50.7	40	10	ACC59609	S aureus
26	15.2	50.7	57	2	AAQ55412	Antifunga
27	15.2	50.7	73	9	AAI56857	Chimeric
28	15.2	50.7	75	2	AAI56857	Chimeric
29	15	50.0	50	11	ADM73587	CGRP-bind
30	15	50.0	50	11	ADM73617	CGRP-bind
31	15	50.0	50	11	ADM73617	CGRP-bind
32	15	50.0	50	11	ADM68138	Oligonuc
33	15	50.0	50	11	ADM68128	Oligonuc
34	15	50.0	50	11	ADM68128	Oligonuc
35	15	50.0	50	11	ADM67859	Rat alpha
36	15	50.0	50	11	ADM67877	Rat alpha
37	15	50.0	50	11	ADM67829	Rat alpha
38	15	50.0	50	11	ADM68139	Oligonuc
39	15	50.0	50	11	ADM68169	Oligonuc
40	15	50.0	60	12	ADQ76911	Escherich
41	14.8	49.3	29	3	AAI93601	Human APC
42	14.8	49.3	34	2	AAI99849	PCR prime
43	14.8	49.3	35	2	AAV27021	Primer GT
44	14.8	49.3	35	2	AAV35868	PCR prime
45	14.8	49.3	35	4	AAI05357	Mouse alp

ALIGNMENTS

RESULT 1
AAA71646
ID AAA71646 standard; DNA; 30 BP.

AC AAA71646;

DT 15-DEC-2000 (first entry)

DE Connexin 43 primer DNA #1.

Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
vulnerable; antiinflammatory; dermatology; site-specific downregulation;
neuronal insult; brain; spinal cord; optic nerve; wound healing;
inflammation reduction; scar formation; epithelial basal cell division;
keratinization; skin rejuvenation; primer; ss.

OS Unidentified.

PN WO200044409-A1.

PD 03-AUG-2000.

PF 27-JAN-2000; 2000WO-GB000238.

PR 27-JAN-1999; 99NZ-00333928.

PR 07-OCT-1999; 99NZ-00500190.

PA (UNLO) UNIV COLLEGE LONDON.

PI Becker DL, Green CR;

DR WPI; 2000-491220/43.

XX New formulation for therapeutic and/or cosmetic treatment of neuronal cell death, inflammation and scar formation, comprises antisense polynucleotide to connexin protein.

XX Claim 9; Page 2; 64pp; English.

PS This invention describes a novel formulation (i) for use in therapeutic and/or cosmetic treatment, comprising at least one antisense polynucleotide (ii) to a connexin protein together with a carrier or vehicle. The products of the invention have neuroprotective, vulnerary, antiinflammatory and dermatological activity. (ii) is useful in a

CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result
 CC of a wound or physical trauma of the brain, spinal cord or optic nerve
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell
 CC division and growth or to regulate outer layer keratinization,
 CC respectively, for skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention
 XX
 SQ Sequence 30 BP; 8 A; 4 C; 8 G; 10 T; 0 U; 0 Other;
 Query Match 100.0%; Score 30; DB 3; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.0021;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTAATTCGGCGAAGAGAAATGTTTCTGTC 30
 Db 1 GTAATTCGGCGAAGAGAAATGTTTCTGTC 30
 RESULT 2
 AAA71647
 ID AAA71647 standard; DNA; 30 BP.
 XX
 AC AAA71647;
 DT 15-DEC-2000 (first entry)
 XX
 DE Connexin 43 primer DNA #2.
 XX
 KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
 KW vulnery; antiinflammatory; dermatology; site-specific downregulation;
 KW neuronal insult; brain; spinal cord; optic nerve; wound healing;
 KW inflammation reduction; scar formation; epithelial basal cell division;
 KW keratinization; skin rejuvenation; primer; ss.
 XX
 OS Unidentified.
 XX
 PN WO200044409-A1.
 XX
 PD 03-AUG-2000.
 XX
 PF 27-JAN-2000; 2000WO-GB000238.
 XX
 PR 27-JAN-1999; 99NZ-00333928.
 PR 07-OCT-1999; 99NZ-00500190.
 XX
 PA (UNLO) UNIV COLLEGE LONDON.
 XX
 PI Becker DL, Green CR;
 XX
 DR WPI; 2000-491220/43.
 XX
 PT New formulation for therapeutic and/or cosmetic treatment of neuronal
 PT cell death, inflammation and scar formation, comprises antisense
 PT polynucleotide to connexin protein.
 XX
 PS Claim 9; Page 2; 64pp; English.
 XX
 CC This invention describes a novel formulation (I) for use in therapeutic
 CC and/or cosmetic treatment, comprising at least one antisense
 CC polynucleotide (II) to a connexin protein together with a carrier or
 CC vehicle. The products of the invention have neuroprotective, vulnery,
 CC antiinflammatory and dermatological activity. (II) is useful in a
 CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death

CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result
 CC of a wound or physical trauma of the brain, spinal cord or optic nerve
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell
 CC division and growth or to regulate outer layer keratinization,
 CC respectively, for skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention
 XX
 SQ Sequence 30 BP; 6 A; 4 C; 10 G; 10 T; 0 U; 0 Other;
 Query Match 89.3%; Score 26.8; DB 3; Length 30;
 Best Local Similarity 93.3%; Pred. No. 0.054; 2; Indels 0; Gaps 0;
 Matches 28; Conservative 0; Mismatches 0;
 QY 1 GTAATTCGGCGAAGAGAAATGTTTCTGTC 30
 Db 1 GTAATTCGGCGAAGAGAAATGTTTCTGTC 30
 RESULT 3
 AAA71652/c
 ID AAA71652 standard; DNA; 30 BP.
 XX
 AC AAA71652;
 DT 15-DEC-2000 (first entry)
 XX
 DE Connexin 43 primer DBIsense DNA.
 XX
 KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
 KW vulnery; antiinflammatory; dermatology; site-specific downregulation;
 KW neuronal insult; brain; spinal cord; optic nerve; wound healing;
 KW inflammation reduction; scar formation; epithelial basal cell division;
 KW keratinization; skin rejuvenation; primer; ss.
 XX
 OS Unidentified.
 XX
 PN WO200044409-A1.
 XX
 PD 03-AUG-2000.
 XX
 PF 27-JAN-2000; 2000WO-GB000238.
 XX
 PR 27-JAN-1999; 99NZ-00333928.
 PR 07-OCT-1999; 99NZ-00500190.
 XX
 PA (UNLO) UNIV COLLEGE LONDON.
 XX
 PI Becker DL, Green CR;
 XX
 DR WPI; 2000-491220/43.
 XX
 PT New formulation for therapeutic and/or cosmetic treatment of neuronal
 PT cell death, inflammation and scar formation, comprises antisense
 PT polynucleotide to connexin protein.
 XX
 PS Example 1; Page 17; 64pp; English.
 XX
 CC This invention describes a novel formulation (I) for use in therapeutic
 CC and/or cosmetic treatment, comprising at least one antisense
 CC polynucleotide (II) to a connexin protein together with a carrier or
 CC vehicle. The products of the invention have neuroprotective, vulnery,
 CC antiinflammatory and dermatological activity. (II) is useful in a
 CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result

CC of a wound or physical trauma of the brain, spinal cord or optic nerve

CC and for decreasing scar formation. (I) containing (II) directed to

CC connexin 43 or 31.1 is administered to regulate epithelial basal cell

CC division and growth or to regulate outer layer keratinization,

CC respectively, for skin rejuvenation or thickening for cosmetic or

CC therapeutic purposes (I) downregulates connexin expression in a highly

CC desirable site-specific manner. This sequence represents a connexin-43

CC directed oligonucleotide which is used in the method of the invention

CC

XX Sequence 30 BP; 10 A; 10 C; 4 G; 6 T; 0 U; 0 Other;

SQ

Query Match 89.3%; Score 26.8; DB 3; Length 30;

Best Local Similarity 93.3%; Pred. No. 0.054;

Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GTAATTGGCGCAAGAGAAATGTTCTGTC 30

Db 30 GTAATTGGCGCAGGAGAAATGTTCTGTC 1

RESULT 4

AAA71653

ID AAA71653 standard; DNA; 30 BP.

XX

AC AAA71653;

XX

DT 15-DEC-2000 (first entry)

XX

DE Chicken connexin 43 primer DB1 DNA.

XX

KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;

KW vulnery; antiinflammatory; dermatology; site-specific downregulation;

KW neuronal insult; brain; spinal cord; optic nerve; wound healing;

KW inflammation reduction; scar formation; epithelial basal cell division;

KW keratinization; skin rejuvenation; primer; chicken; ss.

XX

OS Gallus sp.

XX

XX WC200044409-A1.

PN

PD 03-AUG-2000.

XX

XX 27-JAN-2000; 2000WC-GB000238.

PF

XX 27-JAN-1999; 99NZ-00333928.

PR

XX 07-OCT-1999; 99NZ-00500190.

XX

XX (UNLO) UNIV COLLEGE LONDON.

PA

XX Becker DL, Green CR;

PI

XX WPI; 2000-491220/43.

DR

XX

XX New formulation for therapeutic and/or cosmetic treatment of neuronal

PT cell death, inflammation and scar formation, comprises antisense

PT polynucleotide to connexin protein.

XX

XX Example 1; Page 17; 64pp; English.

PS

XX This invention describes a novel formulation (I) for use in therapeutic

CC and/or cosmetic treatment, comprising at least one antisense

CC polynucleotide (II) to a connexin protein together with a carrier or

CC vehicle. The products of the invention have neuroprotective, vulnerary,

CC antiinflammatory and dermatological activity. (II) is useful in a

CC formulation (I), which is administered to a site on or within a patient

CC for the site-specific downregulation of connexin protein expression. (I)

CC is therefore specifically useful for reducing neuronal cell death

CC resulting from neuronal insult to a specific site in the brain, spinal

CC cord or optic nerve of a patient, for promoting wound healing resulting

CC from trauma, burns or surgery and for reducing inflammation as a result

CC of a wound or physical trauma of the brain, spinal cord or optic nerve

CC and for decreasing scar formation. (I) containing (II) directed to

CC connexin 43 or 31.1 is administered to regulate epithelial basal cell

CC division and growth or to regulate outer layer keratinization,

CC respectively, for skin rejuvenation or thickening for cosmetic or

CC therapeutic purposes (I) downregulates connexin expression in a highly

CC desirable site-specific manner. This sequence represents a connexin-43

CC directed oligonucleotide which is used in the method of the invention

CC

XX Sequence 30 BP; 7 A; 5 C; 9 G; 9 T; 0 U; 0 Other;

SQ

Query Match 57.3%; Score 17.2; DB 3; Length 30;

Best Local Similarity 73.3%; Pred. No. 9.1e+02;

Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 GTAATTGGCGCAAGAGAAATGTTCTGTC 30

Db 1 GTATTACGACAGGAGAAATGTTCTGTC 30

RESULT 5

ADF50888/c

ID ADF50888 standard; DNA; 43 BP.

XX

AC ADF50888;

XX

DT 12-FEB-2004 (first entry)

XX

DE Bacillus subtilis yfhl DNA oligo homologous to sigW.

XX

KW ss; ECF; sigma factor; extracytoplasmic function;

KW autoregulatory promoter; Px; sigW; Pw; detoxification; antimicrobial;

KW bacterial growth; replication; sigX.

XX

OS Bacillus subtilis.

XX

XX US6635475-B1.

PN

XX 21-OCT-2003.

PD

XX 28-JUL-2000; 2000US-00627746.

PF

XX 30-JUL-1999; 99US-0146466P.

PR

XX (CORR) CORNELL RES FOUND INC.

PA

XX Helmann JD;

PI

XX WPI; 2003-810568/76.

DR

XX New Bacillus subtilis sigW gene encoding an extracytoplasmic function

PT alpha factor, useful for screening assays to identify potential

PT antibacterial agents.

XX

XX Disclosure; SEQ ID NO 17; 18pp; English.

PS

XX This invention relates to novel Bacillus subtilis extracytoplasmic

CC function (ECF) sigma factors. These ECF sigma factors regulate their own

CC expression, accordingly the sigX operon is preceded by an autoregulatory

CC promoter named Px and likewise the sigW operon is autoregulated by the W-

CC dependent promoter Pw. A consensus based search approach was used to

CC identify further operons preceded by promoters similar in sequence to Pw

CC and hence recognised by SigW, such that SigW has been shown to control a

CC regulon of more than 30 genes including flotillin and epoxide hydrolase.

CC Specifically, SigW activates a large stationary phase regulon that

CC functions in detoxification and/ or the production of antimicrobial

CC compounds that can be used to modulate bacterial growth and replication.

CC This oligonucleotide sequence is the Bacillus subtilis yfhl DNA that is

CC homologous to sigW of the invention.

XX

SQ Sequence 43 BP; 14 A; 8 C; 8 G; 13 T; 0 U; 0 Other;

Query Match 56.7%; Score 17; DB 10; Length 43;

Best Local Similarity 80.0%; Pred. No. 1.2e+03;

Matches 20; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2 TAATTGGCGCAGAGAAATGTTTC 26
 DB 31 TACGTGCAGAGAGAAATGTTTC 7

RESULT 6
 ADM73609/c
 ID ADM73609 standard; RNA; 50 BP.
 XX
 AC ADM73609;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE CGRP-binding ribo-oligonucleotide STAR-R02-15d-G12.
 XX
 KW antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid;
 KW spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting;
 KW neurogenic inflammation; vasodilation; hypotension; hypertension;
 KW tachycardia; trigeminal afferent sensory neuron activation;
 KW central nociceptive neuron; inflammatory pain; diabetes;
 KW gastric emptying; diabetic gastroparesis; polydipsia; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003093472-A2.
 XX
 PD 13-NOV-2003.
 XX
 PF 06-MAY-2003; 2003WO-EP004746.
 XX
 PR 06-MAY-2002; 2002DE-01020188.
 PR 04-NOV-2002; 2002DE-01051246.
 XX
 PA (CHEF) GRUENENTHAL GMBH.
 PA (NOXX-) NOXXON PHARMA AG.
 XX
 PI Vater A, Maasch C, Jarosch F, Bell M, Helmling S, Bachofaeller B;
 PI Moyroud E, Stark S, Klussmann S, Ruppert T, Schiene K, Bahrenberg G;
 PI Gillen C;
 XX
 DR WPI; 2003-854484/79.
 XX
 XX New antagonists of calcitonin gene-related peptide or amylin, useful for
 PT treating or preventing e.g. migraine or inflammation, are specific
 PT binding nucleic acids.
 XX
 PS Claim 15; SEQ ID NO 196; 263pp; German.

XX This invention describes a novel antagonist of CGRP (calcitonin gene-
 CC related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-
 CC fluoro substituted on pyrimidine nucleotides) was incubated with
 CC biotinylated CGRP for 3 hours at 37degC, then the incubation mixture
 CC applied to a matrix coated with streptavidin for 10 minutes at 37degC.
 CC The matrix was separated, washed with selection buffer and bound RNA
 CC recovered by elution with an excess of non-biotinylated CGRP. The bound
 CC RNA released this way was amplified and the selection procedure repeated
 CC for a total of 18 rounds, after which reverse transcription produced 192
 CC clones. One sequence was present in 168 of these clones. This sequence
 CC had a Kd of 10 nM and was used as starting sequence for preparation of
 CC optimised and truncated RNA aptamers or spiegelmers (STM). Antagonists of
 CC CGRP, amylin and amyloid polypeptides are useful for treating and/or
 CC preventing: migraine, cluster headache, lack of appetite, nausea,
 CC vomiting, neurogenic inflammation (especially where mediated by other
 CC neurotransmitters), vasodilation, hypo- or hyper-tension, tachycardia,
 CC diseases that are associated with activation of trigeminal afferent
 CC sensory neurons and central nociceptive neurons (especially of the higher
 CC pain centres and including chronic inflammatory pain) and/or pain
 CC Generally (chronic, acute, inflammatory, visceral or neuropathic), where
 CC CGRP is the target and hypertension, diabetes, disorders of gastric
 CC emptying, diabetic gastroparesis and polydipsia, where amylin or amyloid
 CC peptides are the target. Antagonists that are nucleic acids are also
 CC useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to
 CC screen for other CGRP and amylin antagonists or agonists, as starting

CC materials for rational drug design, for target validation and for
 CC studying CGRP or amylin function.
 XX
 SQ Sequence 50 BP; 16 A; 9 C; 16 G; 0 T; 9 U; 0 Other;
 Query Match 55.3%; Score 16.6; DB 11; Length 50;
 Best Local Similarity 82.6%; Pred. No. 1.8e+03;
 Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 8 CGGCAGAGAGAAATGTTTCGTC 30
 DB 36 CGTCAGAGAGAAATGTTTC 14

RESULT 7
 ADM68129/c
 ID ADM68129 standard; DNA; 50 BP.
 XX
 AC ADM68129;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Oligonucleotide STAR-R02-15d-G12.
 XX
 KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003093504-A1.
 XX
 PD 13-NOV-2003.
 XX
 PF 06-MAY-2003; 2003WO-EP004747.
 XX
 PR 06-MAY-2002; 2002DE-01020191.
 XX
 PA (NOXX-) NOXXON PHARMA AG.
 XX
 PI Vater A, Jarosch F, Wettich A, Klussmann S;
 XX
 DR WPI; 2003-854487/79.
 XX
 PT Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.
 XX
 PS Example 12; Fig 35; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP, calcitonin
 CC gene-related peptide or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short

CC sequences.
XX Sequence 50 BP; 16 A; 9 C; 16 G; 9 T; 0 U; 0 Other;
SQ

Query Match 55.3%; Score 16.6; DB 11; Length 50;
Best Local Similarity 82.6%; Pred. No. 1.8e+03;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
Oy 8 CGCAGAGAGATGTTCTGTC 30
Db 36 CGTCAAGACGATCGTTCTTTC 14

RESULT 8
ADM67851/c
ID ADM67851 standard; RNA; 50 BP.
XX
AC ADM67851;
XX
DT 03-JUN-2004 (first entry)
XX
DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 94.
XX
KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
KW drug design; primer; ss.
XX
OS Rattus sp.
XX
DN WO2003093504-A1.
XX
PD 13-NOV-2003.
XX
PF 06-MAY-2003; 2003WO-EP004747.
XX
PR 06-MAY-2002; 2002DE-01020191.
XX
PA (NOXX-) NOXXON PHARMA AG.
XX
PI Vater A, Jarosch F, Wettich A, Klusmann S;
XX WPI; 2003-854487/79.
XX
PT Amplification of nucleic acid using two adapters, useful for selection
PT and preparation of aptamers, potential therapeutic agents, with all steps
PT done in one vessel.
XX
PS Example 12; SEQ ID NO 94; 262pp; German.
XX
TC This invention describes a novel method for amplifying nucleic acids. The
CC method comprises 1) preparing a target to be amplified, preferably RNA,
CC having defined 5' and 3' sequences, separated by an intermediate
CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
CC acid (especially one strand of RNA and the other DNA), where the 5'-end
CC of the DNA strand has an overhang at least partly complementary with the
CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
CC least partly complementary with the 3'-end of the target, the second
CC strand also has a cleavage site which can generate a cleavage product
CC that includes the complementary 3'-end of the second strand, 4) the
CC adapters are ligated on the target, 5) reverse transcription is performed
CC and optionally the second strand is synthesised. The products of the
CC invention have antimigraine and analgesic activity. The method is
CC especially used for selection and preparation of nucleic acids including
CC L-nucleic acids, that bind to selected targets (aptamers), potentially
CC useful as therapeutic agents, e.g. as antagonists of CGRP (Calcitonin
CC gene-related peptide) or amylin or their receptors, suitable for
CC treatment of pain, migraine and other conditions, also as starting points
CC for rational drug design, in screening for therapeutic compounds and for
CC target validation. The method can be done in a single vessel, without
CC purification of process intermediates and it can be applied to short
CC sequences. ADM67759-ADM67903 represent oligonucleotides capable of

CC binding to rat CGRP which are used to illustrate the method of the
CC invention.
XX
SQ Sequence 50 BP; 16 A; 9 C; 16 G; 0 T; 9 U; 0 Other;
Oy 8 CGCAGAGAGATGTTCTGTC 30
Db 36 CGTCAAGACGATCGTTCTTTC 14

RESULT 9
ADM73616/c
ID ADM73616 standard; RNA; 49 BP.
XX
AC ADM73616;
XX
DT 03-JUN-2004 (first entry)
XX
DE CGRP-binding ribo-oligonucleotide STAR-R02-15xx-B10.
XX
KW antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid;
KW spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting;
KW neurogenic inflammation; vasodilation; hypotension; hypertension;
KW tachycardia; trigeminal afferent sensory neuron activation;
KW central nociceptive neuron; inflammatory pain; diabetes;
KW gastric emptying; diabetic gastroparesis; polydipsia; ss.
XX
OS Synthetic.
XX
PN WO2003093472-A2.
XX
PD 13-NOV-2003.
XX
PF 06-MAY-2003; 2003WO-EP004746.
XX
PR 06-MAY-2002; 2002DE-01020188.
XX
PR 04-NOV-2002; 2002DE-01051246.
XX
PA (CHEF) GRUENTHAL GMBH.
XX
PI Vater A, Maasch C, Jarosch F, Bell M, Helmling S, Eschgfäller B;
XX Movrcud E, Stark S, Klusmann S, Ruppert T, Schiene K, Bahrenberg G;
XX Gillen C;
XX
XX WPI; 2003-854484/79.
XX
XX New antagonists of calcitonin gene-related peptide or amylin, useful for
XX treating or preventing e.g. migraine or inflammation, are specific
XX binding nucleic acids.
PS Claim 15; SEQ ID NO 193; 263pp; German.
XX
XX This invention describes a novel antagonist of CGRP (calcitonin gene-
XX related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-
XX fluoro substituted on pyrimidine nucleotides) was incubated with
XX biotinylated CGRP for 3 hours at 37degC, then the incubation mixture
XX applied to a matrix coated with streptavidin for 10 minutes at 37degC.
XX The matrix was separated, washed with selection buffer and bound RNA
XX recovered by elution with an excess of non-biotinylated CGRP. The bound
XX RNA released this way was amplified and the selection procedure repeated
XX for a total of 18 rounds, after which reverse transcription produced 192
XX clones. One sequence was present in 168 of these clones. This sequence
XX had a Kd of 10 nM and was used as starting sequence for preparation of
XX optimised and truncated RNA aptamers or spiegelmers (RTM). Antagonists of
XX CGRP, amylin and amyloid polypeptides are useful for treating and/or
XX preventing: migraine, cluster headache, lack of appetite, nausea,
XX vomiting, neurogenic inflammation (especially where mediated by other
XX neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia,

CC diseases that are associated with activation of trigeminal afferent
 CC sensory neurons and central nociceptive neurons (especially of the higher
 CC pain centres and including chronic inflammatory pain) and/or pain
 CC generally (chronic, acute, inflammatory, visceral or neuropathic), where
 CC CGRP is the target and hypertension, diabetes, disorders of gastric
 CC emptying, diabetic gastroparesis and polydipsia, where amylin or amyloid
 CC peptides are the target. Antagonists that are nucleic acids are also
 CC useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to
 CC screen for other CGRP and amylin antagonists or agonists, as starting
 CC materials for rational drug design, for target validation and for
 CC studying CGRP or amylin function.

XX SQ Sequence 49 BP; 16 A; 9 C; 16 G; 0 T; 8 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;

Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAGAAATGTTCTGTC 30

Db 42 TCATCGTCGCTAGCAAGATCGTTCTTTC 14

RESULT 10

ADM73583/c

ID ADM73583 standard; RNA; 49 BP.

XX AC ADM73583;

XX DT 03-JUN-2004 (first entry)

XX CGRP-binding ribo-oligonucleotide STAR-R02-12MW-E3.

XX antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid;
 KW spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting;
 KW neurogenic inflammation; vasodilation; hypotension; hypertension;
 KW tachycardia; trigeminal afferent sensory neuron activation;
 KW central nociceptive neuron; inflammatory pain; diabetes;
 KW gastric emptying; diabetic gastroparesis; polydipsia; ss.

XX Synthetic.

XX WO2003093472-A2.

XX PD 13-NOV-2003.

XX 06-MAY-2003; 2003WO-EP004746.

XX 06-MAY-2002; 2002DE-01020188.

XX 04-NOV-2002; 2002DE-01051246.

XX (CHEF) GRUENTHAL GMBH.

XX (NOXX-) NOXXON PHARMA AG.

XX Vater A, Maasch C, Jarosch F, Bell M, Helmling S, Eschgfäller B;
 PI Meyrout E, Stark S, Klusmann S, Ruppert T, Schiene K, Bahrenberg G;
 PI Gillen C;
 XX WPI; 2003-854484/79.

XX New antagonists of calcitonin gene-related peptide or amylin, useful for
 PT treating or preventing e.g. migraine or inflammation, are specific
 PT binding nucleic acids.

XX Claim 15; SEQ ID NO 160; 263pp; German.

XX This invention describes a novel antagonist of CGRP (calcitonin gene-
 CC related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-
 CC fluoro substituted on pyrimidine nucleotides) was incubated with
 CC biotinylated CGRP, for 3 hours at 37degC, then the incubation mixture
 CC applied to a matrix coated with streptavidin for 10 minutes at 37degC.
 CC The matrix was separated, washed with selection buffer and bound RNA
 CC recovered by elution with an excess of non-biotinylated CGRP. The bound

CC RNA released this way was amplified and the selection procedure repeated
 CC for a total of 18 rounds, after which reverse transcription produced 192
 CC clones. One sequence was present in 166 of these clones. This sequence
 CC had a Kd of 10 nM and was used as starting sequence for preparation of
 CC optimised and truncated RNA aptamers or spiegelmers (RTM). Antagonists of
 CC CGRP, amylin and amyloid polypeptides are useful for treating and/or
 CC preventing: migraine, cluster headache, lack of appetite, nausea,
 CC vomiting, neurogenic inflammation (especially where mediated by other
 CC neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia,
 CC diseases that are associated with activation of trigeminal afferent
 CC sensory neurons and central nociceptive neurons (especially of the higher
 CC pain centres and including chronic inflammatory pain) and/or pain
 CC generally (chronic, acute, inflammatory, visceral or neuropathic), where
 CC CGRP is the target and hypertension, diabetes, disorders of gastric
 CC emptying, diabetic gastroparesis and polydipsia, where amylin or amyloid
 CC peptides are the target. Antagonists that are nucleic acids are also
 CC useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to
 CC screen for other CGRP and amylin antagonists or agonists, as starting
 CC materials for rational drug design, for target validation and for
 CC studying CGRP or amylin function.

XX SQ Sequence 49 BP; 15 A; 8 C; 16 G; 0 T; 10 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;

Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAGAAATGTTCTGTC 30

Db 42 TCATCGTCACAGCAAGATCGTTCTTTC 14

RESULT 11

ADM67858/c

ID ADM67858 standard; RNA; 49 BP.

XX AC ADM67858;

XX DT 03-JUN-2004 (first entry)

XX Rat alpha-D-CGRP binding oligonucleotide SEQ ID 101.

XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.

XX Rattus sp.

XX WO2003093504-A1.

XX PD 13-NOV-2003.

XX 06-MAY-2003; 2003WO-EP004747.

XX 06-MAY-2002; 2002DE-01020191.

XX (NOXX-) NOXXON PHARMA AG.

XX Vater A, Jarosch F, Wettich A, Klusmann S;

XX WPI; 2003-854487/79.

XX Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.

XX Example 12; SEQ ID NO 101; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence. 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end

CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences. ADM67759-ADM67903 represent oligoribonucleotides capable of
 CC binding to rat CGRP which are used to illustrate the method of the
 CC invention.

XX
 SQ Sequence 49 BP; 16 A; 9 C; 16 G; 0 T; 8 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 2; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAAATTTGTTCTGTC 30
 |||||
 Db 42 TCATCGTCTAGACGAATCGTTTCTTC 14

RESULT 12
 ADM68137/c
 ID ADM68137 standard; DNA; 49 BP.

XX AC ADM68137;
 XX DT 03-JUN-2004 (first entry)
 XX DE Oligonucleotide STAR-R02-12NM-E3.
 XX KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 XX KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 XX KW drug design; primer; ss.
 XX OS Synthetic.
 XX PN WO2003093504-A1.
 XX PD 13-NOV-2003.

XX PF 06-MAY-2003; 2003WO-EP004747.
 XX PR 06-MAY-2002; 2002DE-01020191.
 XX PA (NOXX-) NOXXON PHARMA AG.

XX PI Vater A, Jarosch F, Wettich A, Klussmann S;
 XX DR WPI; 2003-854487/79.

XX PT Amplification of nucleic acid using two adapters, useful for selection
 XX and preparation of aptamers, potential therapeutic agents, with all steps
 XX done in one vessel.

XX PS Example 12; Fig 36; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end

CC acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences.

XX SQ Sequence 49 BP; 15 A; 8 C; 16 G; 10 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAAATTTGTTCTGTC 30
 |||||
 Db 42 TCATCGTCTAGACGAATCGTTTCTTC 14

RESULT 13
 ADM68170/c
 ID ADM68170 standard; DNA; 49 BP.

XX AC ADM68170;
 XX DT 03-JUN-2004 (first entry)
 XX DE Oligonucleotide STAR-R02-15xx-B10.

XX KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 XX KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 XX KW drug design; primer; ss.
 XX OS Synthetic.

XX PN WO2003093504-A1.
 XX PD 13-NOV-2003.

XX PF 06-MAY-2003; 2003WO-EP004747.
 XX PR 06-MAY-2002; 2002DE-01020191.

XX PA (NOXX-) NOXXON PHARMA AG.

XX PI Vater A, Jarosch F, Wettich A, Klussmann S;
 XX DR WPI; 2003-854487/79.

XX PT Amplification of nucleic acid using two adapters, useful for selection
 XX and preparation of aptamers, potential therapeutic agents, with all steps
 XX done in one vessel.

XX PS Example 12; Fig 37; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end

CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences.

XX
 SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGGCGCAAGAAATGTTTCGTC 30
 DB 42 TCATCGTCGTAGACGAATCGTTTC 14

RESULT 14

ADM68130/c
 ID ADM68130 standard; DNA; 49 BP.

XX
 AC ADM68130;

DT 03-JUN-2004 (first entry)

DE Oligonucleotide STAR-R02-15d-E1.

XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.

XX Synthetic.

XX WO2003093504-A1.

XX 13-NOV-2003.

XX 06-MAY-2003; 2003WO-EP004747.

XX 06-MAY-2002; 2002DE-01020191.

XX (NOXX-) NOXXON PHARMA AG.

XX Vater A, Jarosch F, Wettich A, Klusmann S;

XX WPI; 2003-854487/79.

XX Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.

XX Example 12; Fig 35; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the

CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences.

SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;

Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGGCGCAAGAAATGTTTCGTC 30
 DB 42 TCATCGTCGTAGACGAATCGTTTC 14

RESULT 15

ADM67825/c

ID ADM67825 standard; RNA; 49 BP.

XX
 AC ADM67825;

DT 03-JUN-2004 (first entry)

DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 68.

XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.

XX Rattus sp.

XX WO2003093504-A1.

XX 13-NOV-2003.

XX 06-MAY-2003; 2003WO-EP004747.

XX 06-MAY-2002; 2002DE-01020191.

XX (NOXX-) NOXXON PHARMA AG.

XX Vater A, Jarosch F, Wettich A, Klusmann S;

XX WPI; 2003-854487/79.

XX Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.

XX Example 12; SEQ ID NO 68; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double


```

;
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/813,507
; FILING DATE: 07-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/032,069
; FILING DATE: 02-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-030100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 576-0200
; TELEFAX: 415 576-0200
; TELEX:
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 41 base pairs
; -TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-813-507-94
;
; Query Match 52.7%; Score 15.8; DB 3; Length 41;
; Best Local Similarity 74.1%; Pred. No. 3.4e+02;
; Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
;
; QY 4 ATTGGCGCAAGAAGATTGTTTCTGTC 30
; DB 12 ATTGGGCTTGATGGATTGTTTCTATC 38
;
; RESULT 3
; US-09-464-453-94
; Sequence 94, Application US/09464453
; Patent No. 6358686
; GENERAL INFORMATION:
; APPLICANT: Lemieux, Bertrand
; Sapolsky, Ronald J.
; TITLE OF INVENTION: Brassica Polymorphisms
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/464,453
; FILING DATE: 14-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/813,507
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-030100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 576-0200
; TELEFAX: 415 576-0200
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 41 base pairs
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-890-363-1
;
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 94:
; US-09-464-453-94
;
; Query Match 52.7%; Score 15.8; DB 3; Length 41;
; Best Local Similarity 74.1%; Pred. No. 3.4e+02;
; Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
;
; QY 4 ATTGGCGCAAGAAGATTGTTTCTGTC 30
; DB 12 ATTGGGCTTGATGGATTGTTTCTATC 38
;
; RESULT 4
; US-09-671-317-510/c
; Sequence 510, Application US/09671317
; Patent No. 6528260
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Cohen, Annick
; TITLE OF INVENTION: BIALLELIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
; FILE REFERENCE: 62.US3.CIP
; CURRENT APPLICATION NUMBER: US/09/671,317
; CURRENT FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 09/536,178
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT/IB00/00403
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 60/126,269
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 60/131,961
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 977
; SOFTWARE: Patent.pm
; SEQ ID NO 510
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 12-456-269 : polymorphic base A or G
; US-09-671-317-510
;
; Query Match 52.7%; Score 15.8; DB 4; Length 47;
; Best Local Similarity 74.1%; Pred. No. 3.5e+02;
; Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
;
; QY 3 AATTCCGCGCAAGAAGATTGTTTCTGT 29
; DB 30 AATTCCGCGTAGAGAGATTCTGCTCT 4
;
; RESULT 5
; US-09-105-390-25/c
; Sequence 25, Application US/09105390
; Patent No. 6288303
; GENERAL INFORMATION:
; APPLICANT: Rodriguez, Raymond
; TITLE OF INVENTION: Rice Beta-Glucanase Enzymes
; TITLE OF INVENTION: and Genes
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Ave., Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
;
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 41 base pairs
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-890-363-1
```

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/105,390
FILING DATE: Filed herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/050,675
FILING DATE: 25-JUN-97
ATTORNEY/AGENT INFORMATION:
NAME: Petithory, Joanne R.
REGISTRATION NUMBER: P42,995
REFERENCE/DOCKET NUMBER: 2000-0455.30
TELEPHONE: 650-324-0880
TELEFAX: 650-324-0960
TELEX:
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 75 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 1...75
OTHER INFORMATION:
US-09-105-390-25

Query Match 50.7%; Score 15.2; DB 3; Length 75;
Best Local Similarity 71.4%; Pred. No. 7.2e+02;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 GTAATTCGGCAGAGAATTTCTG 28
Db 59 GGAATGCTGCAAGGAGCAATGCTACTG 32

RESULT 6
US-09-671-317-596
Sequence 596, Application US/09671317
Patent No. 6528260
GENERAL INFORMATION:
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
APPLICANT: Bougueleret, Lydie
APPLICANT: Cohen, Amick
TITLE OF INVENTION: BIALLIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
FILE REFERENCE: 62.US3.CIP
CURRENT APPLICATION NUMBER: US/09/671,317
CURRENT FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: US 09/536,178
PRIOR FILING DATE: 2000-03-23
PRIOR APPLICATION NUMBER: PCT/IB00/00403
PRIOR FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: US 60/126,269
PRIOR FILING DATE: 1999-03-25
PRIOR APPLICATION NUMBER: US 60/131,961
PRIOR FILING DATE: 1999-04-30
NUMBER OF SEQ ID NOS: 977
SOFTWARE: Patent.pm
SEQ ID NO 596
LENGTH: 47
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: allele
LOCATION: 24
OTHER INFORMATION: 2-11-284 : polymorphic base A or G
US-09-671-317-596

Query Match 49.3%; Score 14.8; DB 4; Length 47;
Best Local Similarity 80.0%; Pred. No. 9.9e+02;
Matches 16; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 11 CAAGAAGAATTTCTGTC 30
Db 20 CAAGAGATTGTGCTATC 39

RESULT 7
US-08-434-001-42/c
Sequence 42, Application US/08434001
Patent No. 5712375
GENERAL INFORMATION:
APPLICANT: JENSEN, KIRK
APPLICANT: CHEN, HANG
APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
NUMBER OF SEQUENCES: 235
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/434,001
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/714,131
FILING DATE: 10-JUNE-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/536,428
FILING DATE: 11-JUNE-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/964,624
FILING DATE: 21-OCTOBER-1992
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-434-001-42

Query Match 49.3%; Score 14.8; DB 1; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3 AATTGGCGCAGAGAATTTCTG 28
Db 55 AATAGCAGCAAGAAATAGGTTTCG 30

RESULT 8

US-08-433-585-42/c
; Sequence 42, Application US/08433585
; Patent No. 5763566
; GENERAL INFORMATION:
; APPLICANT: JENSEN, KIRK
; APPLICANT: CHEN, HANG
; APPLICANT: MORRIS, KEVIN
; APPLICANT: STEPHENS, ANDREW
; APPLICANT: GOLD, LARRY
; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
; TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
; TITLE OF INVENTION: SELEX
; NUMBER OF SEQUENCES: 235
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 8400 E. Prentice Avenue, Suite 200
; CITY: Englewood
; STATE: Colorado
; COUNTRY: USA
; ZIP: 80111

COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/433,585
; FILING DATE:
; CLASSIFICATION: 435

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/536,428
; FILING DATE: 11-JUNE-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/964,624
; FILING DATE: 21-OCTOBER-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Barry J. Swanson
; REGISTRATION NUMBER: 33,215
; REFERENCE/DOCKET NUMBER: NEX30.4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 793-3433
; TELEFAX: (303) 793-3433
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 73 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-433-585-42

Query Match 49.3%; Score 14.8; DB 1; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY

3 AATTGGCGCAAGAAATTGTTCTG 28

DB

55 AATAGCAGCAAGAAATTAGGTTTCGG 30

RESULT 9

US-08-434-425-42/c
; Sequence 42, Application US/08434425
; Patent No. 5789157
; GENERAL INFORMATION:
; APPLICANT: JENSEN, KIRK
; APPLICANT: CHEN, HANG
; APPLICANT: MORRIS, KEVIN
; APPLICANT: STEPHENS, ANDREW
; APPLICANT: GOLD, LARRY

; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
; TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
; TITLE OF INVENTION: SELEX
; NUMBER OF SEQUENCES: 235
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 8400 E. Prentice Avenue, Suite 200
; CITY: Englewood
; STATE: Colorado
; COUNTRY: USA
; ZIP: 80111

COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/434,425
; FILING DATE:
; CLASSIFICATION: 536

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/536,428
; FILING DATE: 11-JUNE-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/964,624
; FILING DATE: 21-OCTOBER-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Barry J. Swanson
; REGISTRATION NUMBER: 33,215
; REFERENCE/DOCKET NUMBER: NEX30.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 793-3433
; TELEFAX: (303) 793-3433
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 73 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-434-425-42

Query Match 49.3%; Score 14.8; DB 1; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY

3 AATTGGCGCAAGAAATTGTTCTG 28

DB

55 AATAGCAGCAAGAAATTAGGTTTCGG 30

RESULT 10

US-08-437-667-42/c
; Sequence 42, Application US/08437667
; Patent No. 5864026
; GENERAL INFORMATION:
; APPLICANT: JENSEN, KIRK
; APPLICANT: CHEN, HANG
; APPLICANT: MORRIS, KEVIN
; APPLICANT: STEPHENS, ANDREW
; APPLICANT: GOLD, LARRY
; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
; TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
; TITLE OF INVENTION: SELEX
; NUMBER OF SEQUENCES: 235
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 8400 E. Prentice Avenue, Suite 200
; CITY: Englewood
; STATE: Colorado
; COUNTRY: USA

QY

3 AATTGGCGCAAGAAATTGTTCTG 28

DB

55 AATAGCAGCAAGAAATTAGGTTTCGG 30

ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/437,667
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/714,131
FILING DATE: 10-JUNE-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/536,428
FILING DATE: 11-JUNE-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/964,624
FILING DATE: 21-OCTOBER-1992
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30.2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-437-667-42

Query Match 49.3%; Score 14.8; DB 2; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Qy 3 AATTGGCGGCAAGAAGATTGTTCTG 28
Db 55 AATAGCAGCAGAAATAGGTTTCGG 30

RESULT 11
US-08-906-955-42/c
Sequence 42, Application US/08906955
Patent No. 6013443
GENERAL INFORMATION:
APPLICANT: HEILIG, JOSEPH S.
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
TITLE OF INVENTION: SELEX
NUMBER OF SEQUENCES: 240
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/906,955
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/714,131
FILING DATE: 10-JUNE-1991

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,001
FILING DATE: 05-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30-5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-906-955-42

Query Match 49.3%; Score 14.8; DB 3; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Qy 3 AATTGGCGGCAAGAAGATTGTTCTG 28
Db 55 AATAGCAGCAGAAATAGGTTTCGG 30

RESULT 12
US-08-945-909-42/c
Sequence 42, Application US/08945909
Patent No. 6114120
GENERAL INFORMATION:
APPLICANT: JENSEN, KIRK
APPLICANT: CHEN, HANG
APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS
TITLE OF INVENTION: ENRICHMENT: TISSUE SELEX
NUMBER OF SEQUENCES: 240
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/945,909
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/06060
FILING DATE: 01-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,425
FILING DATE: 03-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/437,667
FILING DATE: 03-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,001
FILING DATE: 03-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/433,585
FILING DATE: 03-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson

REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30C-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-945-909-42

Query Match 49.3%; Score 14.8; DB 3; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 AATTGGCGCAAGAAGATTGTTCTG 28
DB 55 AATAGCAGCAAGAAATAGGTTTCGG 30

RESULT 13
US-09-396-002A-42/c
; Sequence 42, Application US/09396002A
; Patent No. 6376474
; GENERAL INFORMATION:
; APPLICANT: HEILIG, JOSEPH S.
; GOLD, LARRY
; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
; EXPONENTIAL ENRICHMENT: TISSUE SELEX
; NUMBER OF SEQUENCES: 240
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 1745 Shea Center Drive, Suite 330
; CITY: Highlands Ranch
; STATE: Colorado
; COUNTRY: USA
; ZIP: 80129
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/396,002A
; FILING DATE: 14-Sep-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991
; APPLICATION NUMBER: 08/434,001
; FILING DATE: 05-MAY-1995
; APPLICATION NUMBER: 08/906,955
; FILING DATE: 05-AUGUST-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Barry J. Swanson
; REGISTRATION NUMBER: 33,215
; REFERENCE/DOCKET NUMBER: NEX30-5/D
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 268-0066
; TELEFAX: (303) 268-0065
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 73 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-09-396-002A-42

Query Match 49.3%; Score 14.8; DB 3; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 AATTGGCGCAAGAAGATTGTTCTG 28
DB 55 AATAGCAGCAAGAAATAGGTTTCGG 30

Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 AATTGGCGCAAGAAGATTGTTCTG 28
DB 55 AATAGCAGCAAGAAATAGGTTTCGG 30

RESULT 14
US-10-077-319-42/c
; Sequence 42, Application US/10077319
; Patent No. 6613526
; GENERAL INFORMATION:
; APPLICANT: HEILIG, JOSEPH S.
; GOLD, LARRY
; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
; EXPONENTIAL ENRICHMENT: TISSUE SELEX
; NUMBER OF SEQUENCES: 240
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 1745 Shea Center Drive, Suite 330
; CITY: Highlands Ranch
; STATE: Colorado
; COUNTRY: USA
; ZIP: 80129
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/077,319
; FILING DATE: 14-Feb-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/396,002
; FILING DATE: 14-Sep-1999
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991
; APPLICATION NUMBER: 08/434,001
; FILING DATE: 05-MAY-1995
; APPLICATION NUMBER: 08/906,955
; FILING DATE: 05-AUGUST-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Barry J. Swanson
; REGISTRATION NUMBER: 33,215
; REFERENCE/DOCKET NUMBER: NEX30-5/D
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 268-0066
; TELEFAX: (303) 268-0065
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 73 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-10-077-319-42

Query Match 49.3%; Score 14.8; DB 4; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 AATTGGCGCAAGAAGATTGTTCTG 28
DB 55 AATAGCAGCAAGAAATAGGTTTCGG 30

RESULT 15
PCT-US96-06060-42/c
; Sequence 42, Application PC/TUS9606060
; GENERAL INFORMATION:
; APPLICANT: JENSEN, KIRK
; CHEN, HANG
; ATTORNEY/AGENT INFORMATION:
; NAME: JENSEN, KIRK
; REGISTRATION NUMBER: 33,215
; REFERENCE/DOCKET NUMBER: NEX30-5/D
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 268-0066
; TELEFAX: (303) 268-0065
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 73 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-09-890-363-1

APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
TITLE OF INVENTION: SELEX
NUMBER OF SEQUENCES: 240
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/06060
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/714,131
FILING DATE: 10-JUNE-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/536,428
FILING DATE: 11-JUNE-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/964,624
FILING DATE: 21-OCTOBER-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,425
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/437,667
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,001
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/433,585
FILING DATE: 05-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30/PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US96-06060-42

Query Match 49.3%; Score 14.8; DB 5; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 3 AATTGGCGCAAGAAATGTTCTG 28
Db 55 AATAGCAGCAAGAAATAGGTTTCGG 30

Search completed: November 5, 2004, 17:15:09
Job time : 73 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:47:02 ; Search time 344 Seconds
(without alignments)
469.545 Million cell updates/sec

Title: US-09-890-363-1
Perfect score: 30
Sequence: 1 gaaatgcggcaagaattgtttctgtc 30

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 3611042 seqs, 2692057975 residues

Total number of hits satisfying chosen parameters: 2098264

Minimum DB seq length: 0
Maximum DB seq length: 75

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications NA:*

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq:*
- 3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq:*
- 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
- 6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq:*
- 10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq:*
- 12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq:*
- 13: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq:*
- 14: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq:*
- 15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
- 16: /cgn2_6/ptodata/1/pubpna/US10D_PUBCOMB.seq:*
- 17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq:*
- 18: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq:*
- 19: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq:*
- 20: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
- 21: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	16.2	54.0	60	10	US-09-908-975-8004
2	15.8	52.7	41	14	US-10-043-573-94
3	15.8	52.7	47	16	US-10-294-934-510
4	15.4	51.3	43	15	US-10-032-585-1769
5	15.4	51.3	65	10	US-09-908-975-30222
6	15.2	50.7	73	15	US-10-403-337-33
7	15.2	50.7	73	16	US-10-351-890-33
8	15	50.0	41	16	US-10-035-833A-2017
9	15	50.0	41	16	US-10-035-833A-4612
10	15	50.0	68	13	US-10-027-632-51852
11	15	50.0	68	13	US-10-027-632-51860
12	15	50.0	68	15	US-10-027-632-51852

13	15	50.0	68	15	US-10-027-632-51860
14	14.8	49.3	35	15	US-10-125-994A-68
15	14.8	49.3	43	15	US-10-032-585-1755
16	14.8	49.3	47	16	US-10-294-934-596
17	14.8	49.3	65	10	US-09-908-975-1549
18	14.8	49.3	65	10	US-09-908-975-1579
19	14.8	49.3	73	14	US-10-077-319-42
20	14.6	48.7	21	16	US-10-691-529-49
21	14.6	48.7	50	16	US-10-131-827-3912
22	14.6	48.7	65	10	US-09-908-975-24143
23	14.6	48.7	65	10	US-09-908-975-26971
24	14.6	48.7	65	15	US-10-032-585-2629
25	14.4	48.0	61	10	US-09-907-111-56
26	14.2	47.3	21	16	US-10-691-529-199
27	14.2	47.3	27	10	US-09-911-904-48
28	14.2	47.3	39	14	US-10-194-405-2
29	14.2	47.3	60	10	US-09-908-975-7698
30	14.2	47.3	60	10	US-09-908-975-12139
31	14.2	47.3	60	10	US-09-908-975-12670
32	14.2	47.3	60	10	US-09-908-975-13972
33	14.2	47.3	60	10	US-09-908-975-15633
34	14.2	47.3	60	10	US-09-908-975-22515
35	14.2	47.3	65	10	US-09-908-975-1807
36	14.2	47.3	65	10	US-09-908-975-28469
37	14.2	47.3	69	17	US-10-182-040C-4
38	14.2	47.3	69	17	US-10-182-040C-5
39	14.2	47.3	69	17	US-10-182-040C-6
40	14.2	47.3	69	17	US-10-182-040C-7
41	14	46.7	24	13	US-10-116-288-15
42	14	46.7	25	15	US-10-098-263B-122963
43	14	46.7	27	13	US-10-116-288-16
44	14	46.7	30	13	US-10-116-288-17
45	14	46.7	33	13	US-10-116-288-14

ALIGNMENTS

RESULT 1

US-09-908-975-8004
; Sequence 8004, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; PRIOR FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 8004
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-908-975-8004

Query Match 54.0%; Score 16.2; DB 10; Length 60;
Best Local Similarity 85.7%; Pred. No. 2.9e+03;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3 AATTGGCGCAGAGAAATTGT 23
Db 29 AATGCCCGCAGAGAAAGTGT 49

```

RESULT 2
US-10-043-573-94
; Sequence 94, Application US/10043573
; Publication No. US2003002025A1
; GENERAL INFORMATION:
; APPLICANT: Lemieux, Bertrand
; Sapolsky, Ronald J.
; TITLE OF INVENTION: Brassica Polymorphisms
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/043,573
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/813,507
; FILING DATE: 07-MAR-1997
; APPLICATION NUMBER: US 60/032,069
; FILING DATE: 02-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-030100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 576-0200
; TELEFAX: 415 576-0200
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 41 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 94:

```

```

US-10-043-573-94
Query Match 52.7%; Score 15.8; DB 14; Length 41;
Best Local Similarity 74.1%; Pred. No. 4e+03;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```

```

QY 4 ATTGCGGCAAGAGAAATGTTCTGTC 30
DB 12 ATTGGGCTTGATGATGTTCTATC 38

```

```

RESULT 3
US-10-294-934-510/c
; Sequence 510, Application US/10294934
; Publication No. US20040038231A1
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Cohen, Annick
; TITLE OF INVENTION: BIOMOLECULAR MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
; FILE REFERENCE: 62.USA.DIV
; CURRENT APPLICATION NUMBER: US/10/294,934
; CURRENT FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 09/671,317
; PRIOR FILING DATE: 2000-09-27

```

```

; PRIOR APPLICATION NUMBER: US 09/536,178
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT/IB00/00403
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 60/126,269
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 60/131,961
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 977
; SOFTWARE: Patent.pm
; SEQ ID NO 510
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 12-456-269 : polymorphic base A or G
US-10-294-934-510

```

```

Query Match 52.7%; Score 15.8; DB 16; Length 47;
Best Local Similarity 74.1%; Pred. No. 4.1e+03;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```

```

QY 3 AATTGCGGCAAGAGAAATGTTCTGT 29
DB 30 AATTCCVGTAGAGAAATTCCTGCTCT 4

```

```

RESULT 4
US-10-032-585-1769
; Sequence 1769, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 1769
; LENGTH: 43
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-1769

```

```

Query Match 51.3%; Score 15.4; DB 15; Length 43;
Best Local Similarity 76.0%; Pred. No. 6e+03;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```

```

QY 5 TTGCGGCAAGAGAAATGTTCTGT 29
DB 1 TTACGACAGACAAATGGAATCTAT 25

```

```

RESULT 5
US-09-908-975-30222
; Sequence 30222, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975

```

;

CUKKE.

```

Query Match      50.0%; Score 15; DB 16; Length 41;
Best Local Similarity 72.0%; Pred. No. 9e-03;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAAGATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 38 TAATTACAGCAATATGATGTTTTC 14

RESULT 10
US-10-027-632-51852
; Sequence 51852, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-08-09
; PRIOR APPLICATION NUMBER: US 60/146,002
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51852
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51852

Query Match      50.0%; Score 15; DB 13; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAAGATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 10 TAATGAGGCAATAGAAACSAATTC 34

RESULT 11
US-10-027-632-51860
; Sequence 51860, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51860
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51860

Query Match      50.0%; Score 15; DB 15; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAAGATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 10 TAATGAGGCAATAGAAACSAATTC 34

RESULT 12
US-10-027-632-51852
; Sequence 51852, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51852
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51852

Query Match      50.0%; Score 15; DB 15; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAAGATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 10 TAATGAGGCAATAGAAACSAATTC 34

RESULT 13
US-10-027-632-51860
; Sequence 51860, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 1999-11-23

```

```

; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51860
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51860

Query Match      50.0%; Score 15; DB 13; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAAGATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 10 TAATGAGGCAATAGAAACSAATTC 34

RESULT 12
US-10-027-632-51852
; Sequence 51852, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51852
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51852

Query Match      50.0%; Score 15; DB 15; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAAGATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 10 TAATGAGGCAATAGAAACSAATTC 34

RESULT 13
US-10-027-632-51860
; Sequence 51860, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 1999-11-23

```

```
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51860
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51860

Query Match          50.0%; Score 15; DB 15; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 2 TAATTGGCGCAAGAGAAATTGTTTC 26
Db 10 TAAATGAGGCATAAGAACATTC 34

RESULT 14
US-10-125-994A-68
; Sequence 68; Application US/10125994A
; Publication No. US20030203427A1
; GENERAL INFORMATION:
; APPLICANT: Koike, Chihiro
; TITLE OF INVENTION: ALPHA 1.3-GALACTOSYLTRANSFERASE GENE AND PROMOTER
; FILE REFERENCE: 206779
; CURRENT APPLICATION NUMBER: US/10/125,994A
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: PCT/US00/29139
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: US 60/227,951
; PRIOR FILING DATE: 2000-09-25
; PRIOR APPLICATION NUMBER: US 60/161,092
; PRIOR FILING DATE: 1999-10-22
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn version 3.0.
; SEQ ID NO 68
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for identifying murine exons 2 and 3
US-10-125-994A-68

Query Match          49.3%; Score 14.8; DB 15; Length 35;
Best Local Similarity 73.1%; Pred. No. 1.1e-04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 5 TTGCGGCAAGAGAAATTGTTTCTGTC 30
Db 6 TTGAGGATCCCAAGACTTGTCTGAC 31

RESULT 15
US-10-032-585-1755/c
; Sequence 1755; Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1755
; LENGTH: 43
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-1755

Query Match          49.3%; Score 14.8; DB 15; Length 43;
Best Local Similarity 88.9%; Pred. No. 1.1e-04;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 12 AAGAAGAAATTTGTTTCTGT 29
Db 42 AAGAAGAACTTGTTTTGT 25

Search completed: November 5, 2004, 17:21:01
Job time : 347 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:28:19 ; Search time 2315 Seconds
(without alignments)
472.221 Million cell updates/sec

Title: US-09-890-363-1

Perfect score: 30

Sequence: 1 gtaattcgccgaagaattgtttctgtc 30

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 389094

Minimum DB seq length: 0

Maximum DB seq length: 75

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST:*

1: gb_est1:*

2: gb_est2:*

3: gb_hic:*

4: gb_est3:*

5: gb_est4:*

6: gb_est5:*

7: gb_est6:*

8: gb_gss1:*

9: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	17.4	58.0	37	8	A2333195	A2333195 1M0062G09
2	15.6	52.0	70	7	T87927	T87927 ye08c07.r1
3	15.4	51.3	62	1	AL024389	AL024389 r8421a45
4	15.4	51.3	67	1	AA591826	AA591826 vi49e12.r
5	15.4	51.3	70	6	CD881894	CD881894 F1.104K17
6	15.4	51.3	70	8	BH865903	BH865903 SALK.1000
7	15.4	51.3	75	1	AU014056	AU014056 AU014056
8	15.2	50.7	39	8	BH098815	BH098815 SALK.0561
9	15.2	50.7	49	9	AU599937	AU599937 Arabidops
10	15.2	50.7	74	1	AA704411	AA704411 zj21h01.s
11	15.2	50.7	74	7	CF853347	CF853347 pSMC008xH
12	15.0	50.0	41	8	BH856306	BH856306 SALK.0799
13	15.0	50.0	58	1	AA554039	AA554039 nk95G03.s
14	15.0	50.0	75	4	BH341762	BH341762 fw52e08.y
15	14.8	49.3	39	2	B535115	B535115 601231231
16	14.8	49.3	44	8	A6222559	A6222559 1M0459F24
17	14.8	49.3	59	8	BZ769592	BZ769592 SALK.1424
18	14.8	49.3	60	1	AA388795	AA388795 vb25C07.r
19	14.8	49.3	61	1	A1829969	A1829969 wj85b06.x
20	14.8	49.3	63	7	N23930	N23930 YX85a12.s1
21	14.6	48.7	52	2	B5633547	B5633547 NF057G03D
22	14.6	48.7	54	8	BH812420	BH812420 SALK.0617
23	14.6	48.7	62	9	CG667820	CG667820 OST462327
24	14.6	48.7	64	4	BI097338	BI097338 SWOY3MCAM

C 25	14.6	48.7	67	9	CC795622	CC795622 SALK.0875
26	14.6	48.7	69	6	CD028982	CD028982 mgns007xf
27	14.6	48.7	72	4	BJ057828	BJ057828 BX637533
28	14.6	48.7	73	5	EX697533	EX697533 SWBmfCAV
29	14.6	48.7	73	9	CB832531	CB832531 SWBmfCAV
30	14.6	48.7	73	9	CG495277	CG495277 OST34591
31	14.6	48.7	74	7	CN862695	CN862695 000903AAL
32	14.6	48.7	75	2	AW247813	AW247813 2820447.3
33	14.4	48.0	42	1	AU268709	AU268709 AU268709
34	14.4	48.0	45	6	CA967668	CA967668 CcLQ03a10
35	14.4	48.0	68	1	AV852289	AV852289 AV852289
36	14.4	48.0	68	8	AZ521506	AZ521506 1006030C0
37	14.4	48.0	73	5	BH070927	BH070927 C021E02.P
38	14.4	48.0	74	8	AZ576247	AZ576247 AST-TD1AS
39	14.4	48.0	75	6	CD744649	CD744649 IRB17.A12
40	14.2	47.3	37	4	BJ066419	BJ066419 BJ066419
41	14.2	47.3	50	8	BZ664415	BZ664415 SALK.0710
42	14.2	47.3	50	8	BZ664418	BZ664418 SALK.0711
43	14.2	47.3	52	8	AZ694935	AZ694935 TE-389-3
44	14.2	47.3	54	2	BF450060	BF450060 maa46c07.
45	14.2	47.3	54	8	BZ761965	BZ761965 SALK.0817

ALIGNMENTS

RESULT 1
AZ333195/c
LOCUS
DEFINITION
AZ333195
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source

AZ333195 37 bp DNA linear GSS 29-SEP-2000
1M0062G09F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0062G09 F, genomic survey sequence.
AZ333195
GSS.
AZ333195.1 GI:10397573
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islan,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0062 row: G column: 09
Seq primer: CGTTGTAACGACGCGCCAGT
Class: plasmid ends
High quality sequence stop: 37.
Location/Qualifiers
1..37
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0062G09"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (Gill4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN

Query Match 58.0%; Score 17.4; DB 8; Length 37;
Best Local Similarity 77.8%; Pred. No. 5.7e+03;
Matches 21; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAGAAATGTTCTG 28

Db 32 TAATTGCGGCAAGAGATGTTGTTG 6

RESULT 2

LOCUS

DEFINITION YAC8C07.r1 Stratagene lung (#937210) homo sapiens CDNA clone IMAGE111732.5, similar to gb:M68519 rat PULMONARY SURFACTANT-ASSOCIATED PROTEIN A PRECURSOR (HUMAN); mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 70)
Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiapelli, B., Chissole, S., Dietrich, N., Dubuque, T., Favello, A., Gish, W., Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N., Mardis, E., Moore, B., Nottis, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J., Travaskis, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R. and Marra, M.

TITLE

JOURNAL

MEDLINE

COMMENT

Generation and analysis of 280,000 human expressed sequence tags
Genome Res. 6 (9), 807-828 (1996)
889549
Contact: Wilson RK
Washington University School of Medicine
444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 570
High quality sequence starts: 1 High quality sequence stops: 1
Source: IMAGE Consortium, LNL, this clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information. Trace considered overall poor quality
Insert Length: 570 Std Error: 0.00
Seq primer: M13Rpl
High quality sequence stop: 1.
Location/Qualifiers
1..70
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:485421"
/db_xref="taxon:9606"
/clone="IMAGE:117132"
/sex="male"

FEATURES

source

Query Match 51.3%; Score 15.4; DB 1; Length 62;
Best Local Similarity 76.0%; Pred. No. 4.7e+04;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 GTAATTGCGGCAAGAGAAATGTTT 25

/dev_stage="72 years"
/lab_host="SOLR cells (kanamycin resistant)"
/clone_lib="Stratagene lung (#937210)"
/note="Organ: lung; Vector: paluescript SK-; Site 1: EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer: Oligo dT, normal lung. Average insert size: 1.0 kb; Uni-ZAP XR Vector; -5' adaptor sequence: 5' GAATTCGGCAGG 3' ~3' adaptor sequence: 5' CTCGAGTTTTTTTTTTTTTTT 3'"

ORIGIN

Query Match 52.0%; Score 15.6; DB 7; Length 70;
Best Local Similarity 70.0%; Pred. No. 3.9e+04;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 1 GTAATTGCGGCAAGAGAAATGTTCTGTC 30

Db 31 GAATAGGATAGATAGATCTGTTCTGTC 60

RESULT 3

LOCUS

DEFINITION AL024389 62 bp mRNA linear EST 29-DEC-1999 r8421a45 Beddington mouse dissected endoderm Mus musculus CDNA clone 528-7J11 5', mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 62)
Harrison, S.M., Dunwoodie, S.L., Arkell, R.M., Lehrach, H. and Beddington, R.S.
Isolation of novel tissue-specific genes from cDNA libraries representing the individual tissue constituents of the gastrulating mouse embryo
Development 121 (8), 2479-2489 (1995)
95401865
7671812

JOURNAL

MEDLINE

COMMENT

Contact: Wiles, M., Lehrach, H. and Avner, P.
EEC Mouse Transcript Mapping Consortium
Genoscope - CNS
2, rue Gaston Cremieux, 91000 Evry, France
Email: pavner@pasteur.fr
clone available from Ressourcenzentrum, Heubnerweg 6, D-14059 Berlin, Germany. Web site http://www.rzpd.de
Seq primer: CCGTCCGGAATCCCGGT,
High quality sequence only submitted.
Vector: pSport1; site 1: NotI; site 2: SalI;
Cloned unidirectionally.
Dissected endoderm 7.5 days.
Average insert size: 1.2 kb (range: 0.2 - 2.kb).
Location/Qualifiers
1..62
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6 x DBA"
/db_xref="taxon:10090"
/clone="528-7J11"
/tissue_type="dissected endoderm"
/dev_stage="7.5 dpc"
/clone_lib="Beddington mouse dissected endoderm"
/note="Vector: pSport1; Site 1: NotI; Site 2: SalI; Cloned unidirectionally.~ High quality sequence only submitted.~ Average insert size: 1.2 kb (range: 0.2 - 2.kb)"

FEATURES

source

Query Match 51.3%; Score 15.4; DB 1; Length 62;
Best Local Similarity 76.0%; Pred. No. 4.7e+04;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 GTAATTGCGGCAAGAGAAATGTTT 25

T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

22363535

PUBMED

12446565

REFERENCE

2 (bases 1 to 49)

Balzarque,S.

Direct Submission

Submitted (23-OCT-2003) Balzarque S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 31057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.inbiolegen.fr>).

FEATURES

Location/Qualifiers

1..49

/organism="Arabidopsis thaliana"

/mol_type="Genomic DNA"

/cultivar="Wassiliewskij"

/db_xref="taxon:3702"

/clone="496H09"

/clone_lib="Arabidopsis thaliana T-DNA insertion lines"

1..49

/note="T-DNA flanking sequence left border"

misc_feature

1..49

/note="T-DNA flanking sequence left border"

ORIGIN

Query Match 50.7%; Score 15.2; DB 9; Length 49;

Best Local Similarity 71.4%; Pred. No. 5.6e+04;

Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAGAGAAATGTTCTCTGT 29

|||||

Db 15 TAGTTGCGAATGTAGAATCCTTTTGT 42

RESULT 10

-AA704411/c

LOCUS

DEFINITION

zj21h01.sl Soares fetal liver spleen INFLS_S1 Homo sapiens cDNA clone IMAGE:450961 3', mRNA sequence.

AA704411

ACCESSION

AA704411.1 GI:2714329

KEYWORDS

EST.

SOURCE

Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE

1 (bases 1 to 74)

Hillier,L., Allen,M., Bowles,L., Dubuque,T., Geisels,G., Jost,S., Krizman,D., Kucaba,T., Lay,M., Le,N., Lennon,G., Marra,M., Martin,J., Moore,B., Schellenberg,K., Sceptoe,M., Tan,F., Theising,B., White,Y., Wylie,T., Waterston,R. and Wilson,R. WashU-NCI human EST Project

Unpublished (1997)

TITLE

JOURNAL

COMMENT

Contact: Wilson RK

Washington University School of Medicine

444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@watson.wustl.edu

This clone is available royalty-free through INL; contact the IMAGE Consortium (info@image.lnlnl.gov) for further information.

Seq primer: -40m13 fwd ET from Amersham

High quality sequence stop: 52.

Location/Qualifiers

FEATURES

Location/Qualifiers

1..74

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="GDB:1387317"

/db_xref="taxon:9606"

/clone="IMAGE:450961"

/sex="male"

/dev_stage="20 week post conception fetus"

/lab_host="DH10B (ampicillin resistant)"

/clone_lib="Soares fetal liver spleen INFLS_S1"

/note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site 1: Pac I; Site 2: Eco RI; This is a subtracted version of the original Soares fetal liver spleen INFLS library. 1st strand cDNA was primed with a Pac I - oligo(dT) primer [5'-TTTTTTTTTTT 3'] AACTCGAAGATTAAATTAAGATCTTTTTTTTTTTTTTTT 3'] double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Pac I and cloned into the Pac I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo."

Query Match 50.7%; Score 15.2; DB 1; Length 74;

Best Local Similarity 71.4%; Pred. No. 5.9e+04;

Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 3 AATTGGCGCAGAGAAATGTTCTCTGTC 30

|||||

Db 34 ATTATGGCAATAAAATTTTTTTTGTGTC 7

RESULT 11

CF853347

LOCUS

DEFINITION

CF853347.1 74 bp mRNA linear EST 30-OCT-2003 pSMC008XH16f USDA-IPAFS:Expression of Phytophthora sojae genes during infection and propagation_SMC Phytophthora sojae cDNA clone SMC008H16 5', mRNA sequence.

CF853347

ACCESSION

CF853347.1 GI:38069001

VERSION

EST.

KEYWORDS

Phytophthora sojae

SOURCE

Phytophthora sojae

ORGANISM

Eukaryota; stramenopiles; Oomycetes; Pythiales; Pythiaceae; Phytophthora.

1 (bases 1 to 74)

Tyler,B. Not Published

Tyler,B. Not Published

Unpublished (2003)

COMMENT

Contact: Tyler B

Tyler lab

VBI

1880 Pratt Dr., Blacksburg, VA 24061, USA

Tel: 540-231-7318

Email: bmyler@vt.edu

PCR Primers

FORWARD: M13 reverse 17mer at 5' end

BACKWARD: M13 reverse 17mer at 5' end

Plate: 008 row: H column: 16

Seq primer: M13 reverse 17mer at 5' end

High quality sequence stop: 74.

Location/Qualifiers

1..74

/organism="Phytophthora sojae"

/mol_type="mRNA"

/db_xref="taxon:67593"

/clone="SMC008H16"

/tissue_type="mycelium"

/cell_line="P6497"

/dev_stage="synthetic medium"

/lab_host="USDA-IPAFS:Expression of Phytophthora sojae genes during infection and propagation_SMC"

source

FEATURES

source

/note="Vector: pCMV-SPORT6.1; Site_1: SalI; Site_2: NotI"

```

ORIGIN
Query Match      50.7%; Score 15.2; DB 7; Length 74;
Best Local Similarity 85.0%; Pred. No. 5.9e+04;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3 AATTGCGGCAAGAGAAATTG 22
    |||||
Db 31 AACTGCGGCAAGAGAAATG 50
    |||||

RESULT 12
BH856306          41 bp      DNA      linear      GSS 08-JUL-2002
LOCUS            SALK_079956.50.05.x Arabidopsis thaliana TDNA insertion lines
DEFINITION       Arabidopsis thaliana genomic clone SALK_079956.50.05.x, genomic
survey sequence.
ACCESSION        BH856306
KEYWORDS         GSS.
SOURCE           Arabidopsis thaliana (thale cress)
ORGANISM         Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
REFERENCE        1 (bases 1 to 41)
AUTHORS          Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednisi,L.,
Shinn,P., Zimmerman,J. and Ecker,J.R.
TITLE            A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome
JOURNAL           Unpublished (2001)
COMMENT          Contact: Joseph R. Ecker
                  Salk Institute Genomic Analysis Laboratory (SIGAL)
                  The Salk Institute for Biological Studies
                  10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
                  Tel: 858 453 4100 x1752
                  Fax: 858 558 6379
                  Email: ecker@salk.edu
                  This is single pass sequence recovered from the left border of
                  TDNA.
FEATURES          Class: TDNA tagged.
                  Location/Qualifiers
                    source          1..41
                    /organism="Arabidopsis thaliana"
                    /mol_type="genomic DNA"
                    /ecotype="Col-0"
                    /db_xref="taxon:3702"
                    /clone="SALK_079956.50.05.x"
                    /clone_lib="Arabidopsis thaliana TDNA insertion lines"
                    /note="PCR was performed on Arabidopsis thaliana lines
                    each of which contains one or more TDNA insertion
                    elements. The resultant fragment for each line was
                    directly sequenced to determine the genomic sequence at
                    the site of insertion. Details of the protocols used can
                    be found at http://signal.salk.edu/tdna_protocols.html"

ORIGIN
Query Match      50.0%; Score 15; DB 8; Length 41;
Best Local Similarity 78.3%; Pred. No. 6.7e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAGAAATTGTT 24
    |||||
Db 3 TAATTAGGAAGAAATATTTT 25
    |||||

RESULT 13
AA554039          58 bp      mRNA      linear      EST 09-SEP-1997
LOCUS            nx95q03.s1 NCI-CGAP Coll1 Homo sapiens cDNA clone IMAGE:1028596 3'
DEFINITION       similar to SW:ATP6_HUMAN P00846 ATP SYNTHASE A CHAIN 1, mRNA

/note="Vector: pCMV-SPORT6.1; Site_1: SalI; Site_2: NotI"

ORIGIN
Query Match      50.7%; Score 15.2; DB 7; Length 74;
Best Local Similarity 85.0%; Pred. No. 5.9e+04;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3 AATTGCGGCAAGAGAAATTG 22
    |||||
Db 31 AACTGCGGCAAGAGAAATG 50
    |||||

RESULT 12
BH856306          41 bp      DNA      linear      GSS 08-JUL-2002
LOCUS            SALK_079956.50.05.x Arabidopsis thaliana TDNA insertion lines
DEFINITION       Arabidopsis thaliana genomic clone SALK_079956.50.05.x, genomic
survey sequence.
ACCESSION        BH856306
KEYWORDS         GSS.
SOURCE           Arabidopsis thaliana (thale cress)
ORGANISM         Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
REFERENCE        1 (bases 1 to 41)
AUTHORS          Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednisi,L.,
Shinn,P., Zimmerman,J. and Ecker,J.R.
TITLE            A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome
JOURNAL           Unpublished (2001)
COMMENT          Contact: Joseph R. Ecker
                  Salk Institute Genomic Analysis Laboratory (SIGAL)
                  The Salk Institute for Biological Studies
                  10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
                  Tel: 858 453 4100 x1752
                  Fax: 858 558 6379
                  Email: ecker@salk.edu
                  This is single pass sequence recovered from the left border of
                  TDNA.
FEATURES          Class: TDNA tagged.
                  Location/Qualifiers
                    source          1..41
                    /organism="Arabidopsis thaliana"
                    /mol_type="genomic DNA"
                    /ecotype="Col-0"
                    /db_xref="taxon:3702"
                    /clone="SALK_079956.50.05.x"
                    /clone_lib="Arabidopsis thaliana TDNA insertion lines"
                    /note="PCR was performed on Arabidopsis thaliana lines
                    each of which contains one or more TDNA insertion
                    elements. The resultant fragment for each line was
                    directly sequenced to determine the genomic sequence at
                    the site of insertion. Details of the protocols used can
                    be found at http://signal.salk.edu/tdna_protocols.html"

ORIGIN
Query Match      50.0%; Score 15; DB 8; Length 41;
Best Local Similarity 78.3%; Pred. No. 6.7e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAGAAATTGTT 24
    |||||
Db 3 TAATTAGGAAGAAATATTTT 25
    |||||

RESULT 13
AA554039          58 bp      mRNA      linear      EST 09-SEP-1997
LOCUS            nx95q03.s1 NCI-CGAP Coll1 Homo sapiens cDNA clone IMAGE:1028596 3'
DEFINITION       similar to SW:ATP6_HUMAN P00846 ATP SYNTHASE A CHAIN 1, mRNA

```

```

sequence.
ACCESSION        AA554039
VERSION          AA554039.1 GI:2324578
KEYWORDS         EST.
SOURCE           Homo sapiens (human)
ORGANISM         Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE        1 (bases 1 to 58)
AUTHORS          NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE            National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL           Unpublished (1997)
COMMENT          Contact: Robert Strausberg, Ph.D.
                  Email: cgaps-remail.nih.gov
                  Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Elias Campo,
                  M.D., Michael R. Emmert-Buck, M.D., Ph.D.
                  cDNA Library Preparation: Stratagene, Inc.
                  cDNA Library Arrayed by: Greg Lennon, Ph.D.
                  DNA Sequencing by: Washington University Genome Sequencing Center
                  Clone distribution: NCI-CGAP clone distribution information can be
                  found through the I.M.A.G.E. Consortium/LLNL at:
                  www-bio.llnl.gov/bbrp/image/image.html
Trace considered overall poor quality
Insert Length: 1186 Std Error: 0.00
Seq primer: -40ml3 fwd. Et from Amersham
High quality sequence stop: 1.
Location/Qualifiers
  source          1..58
  /organism="Homo sapiens"
  /mol_type="mRNA"
  /db_xref="taxon:9606"
  /clone="IMAGE:1028596"
  /tissue_type="tumor"
  /lab_host="SOLR (kanamycin resistant)"
  /clone_lib="NCI CGAP Coll1"
  /note="Organ: colon; Vector: Bluescript SK-; Site 1:
  EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer:
  GGAATG di. Multiple colon tumors. 5' adaptor sequence: 5'
  CTAATCGGCACGAG 3' 3' adaptor sequence: 5'
  CTCGAGTTTTTTTTTTTTTTT 3' Average insert size: 1.1 kb."

ORIGIN
Query Match      50.0%; Score 15; DB 1; Length 58;
Best Local Similarity 78.3%; Pred. No. 7e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAGAAATTGTT 24
    |||||
Db 25 TAGTTGTGCAATACCAATGTT 47
    |||||

RESULT 14
BM341762          75 bp      mRNA      linear      EST 07-JAN-2002
LOCUS            fw52e08.y1 zebrafish SJD day 3 embryo Danio rerio cDNA clone
DEFINITION       IMAGE:5568470 5', mRNA sequence.
ACCESSION        BM341762
VERSION          BM341762.1 GI:18078462
KEYWORDS         EST.
SOURCE           Danio rerio (zebrafish)
ORGANISM         Danio rerio
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
Cypriniformes; Cyprinidae; Danio.
REFERENCE        1 (bases 1 to 75)
AUTHORS          Clark,M., Johnson,S.L., Lehrach,H., Lee,R., Li,F., Marra,M.,
                  Eddy,S., Hillier,L., Kucaba,T., Martin,J., Beck,C., Wyllie,T.,
                  Underwood,K., Steptoe,M., Theising,B., Allen,M., Bowers,Y.,
                  Person,B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schurk,R.,
                  Ritter,E., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R.,
                  Waterston,R. and Wilson,R.

```

TITLE WashU Zebrafish EST Project 1998
 JOURNAL Unpublished (1998)
 COMMENT Contact: Stephen L. Johnson
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: zbrafish@watson.wustl.edu
 cDNA Library construction by: Joe Barnes and Steve Johnson. DNA
 Sequencing by: Washington University Genome Sequencing Center Clome
 distribution: Research Genetics web address:
<http://www.researchgenetics.com/>
 Putative full length read
 The vector to vector length is 76
 Seq primer: T3 ET from Amersham.
 Location/Qualifiers

FEATURES

source

1. .75
 /organism="Danio rerio"
 /mol_type="mRNA"
 /strain="SJD"
 /db_xref="taxon:7955"
 /clone="IMAGE:5568470"
 /tissue_type="embryo, day 3"
 /lab_host="DH10B"
 /clone_lib="Zebrafish SJD day 3 embryo"
 /note="Vector: pAMP1; Site 1: EcoRI; Site 2: NotI; First
 strand cDNA synthesis was primed using oligo-dT on
 magnetic beads with an additional primer
 5'-ggcgccgtatcagctactactatagg-3'. Second strand
 synthesis was a 3-cycle PCR using the primers
 5'-ggcgccgtatcagctactactatag-3' and
 5'-aagcagtggttaacacgcagactactt-tttttttttttn-3'. cDNA
 was subsequently amplified in a 7-cycle PCR with the
 following primers: 5'-ggcgccgtatcagctactactag-3' and
 5'-aagcagtggtt-aacacgcag. Deoxy-UMP adaptors were added in
 a third PCR (5 cycles) and the primers
 5'-caucaucauacgcgcgtatcagctactactaggg-3' and
 5'-cucaucaucauacgcgtgttaacacgcagactac-3'. Ends were
 treated with uracil DNA glycosylase and product with 3'
 overhangs was annealed to complementary ends of pAMP1.
 Insert can be excised using EcoRI and NotI. Library
 constructed by Joe Barnes and Steve Johnson (Washington
 University)."

ORIGIN

Query Match 50.0%; Score 15; DB 4; Length 75;
 Best Local Similarity 78.3%; Pred. No. 7.2e+04;
 Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Dy 3 AATTGCGGCAAGAGAAATTGTTT 25
 ||||| ||||| ||||| |||||
 Db 12 AATTAGAAAAGAGAGATTGTTT 34

RESULT 15
 BE535115
 LOCUS 601231231F1 NC1_CGAP_Mam6 Mus musculus cDNA clone IMAGE:3595207 5',
 DEFINITION mRNA sequence.
 BE535115 39 bp mRNA linear EST 09-AUG-2000
 BE535115.1 GI:9763760
 ACCESSION
 VERSION
 KEYWORDS EST.
 SOURCE Mus musculus (house mouse)
 ORGANISM
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
 1 (bases 1 to 39)
 NIH-MSC <http://mgc.nci.nih.gov/>
 National Institutes of Health, Mammalian Gene Collection (MGC)
 Unpublished (1999)
 JOURNAL
 TITLE
 AUTHORS
 CONTACT: Robert Strausberg, Ph.D.
 Email: cgapbs-r@mail.nih.gov
 Tissue Procurement: Jeffrey Green M.D.

cDNA Library Preparation: Life Technologies, Inc.
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
 DNA Sequencing by: Incyte Genomics, Inc.
 Clome distribution: MGC clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL at:
<http://image.llnl.gov>
 Plate: LLAM8770 row: n column: 08
 High quality sequence spot: 37.
 Location/Qualifiers

FEATURES

source

1. .39
 /organism="Mus musculus"
 /mol_type="mRNA"
 /strain="FVB/N"
 /db_xref="taxon:10090"
 /clone="IMAGE:3595207"
 /sex="female, virgin"
 /tissue_type="infiltrating ductal carcinoma"
 /dev_stage="5 months"
 /lab_host="DH10B"
 /clone_lib="NCI CGAP Mam6"
 /note="Organ: mammary; Vector: pCMV-SPORT6; Site 1: SalI;
 Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT.
 Library constructed by Life Technologies, Investigator
 providing samples: Jeffrey Green, M.D., NIH"

ORIGIN

Query Match 49.3%; Score 14.8; DB 2; Length 39;
 Best Local Similarity 73.1%; Pred. No. 8.2e+04;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Dy 3 AATTGCGGCAAGAGAAATTGTTTCTG 28
 ||||| ||||| ||||| |||||
 Db 5 AATAAAGGCAAGAAAATTGCTGATG 30

Search completed: November 5, 2004, 17:13:58
 Job time : 2324 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 5, 2004, 20:41:18 ; Search time 43 Seconds
(without alignments)
157.312 Million cell updates/sec

Title: US-09-882-434A-1
Perfect score: 551
Sequence: 1 MASTKLFPSVITVMVLIAA.....FGSARACNPFQWKSFIQC 102

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA:*
1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep.*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep.*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep.*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep.*
5: /cgn2_6/ptodata/1/iaa/PTUS_COMB.pep.*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	75.5	13.7	486	4	US-08-169-613A-2
2	75.5	13.7	486	4	US-08-622-191-8
3	75.5	13.5	486	1	US-07-872-678A-48
4	74.5	13.5	908	4	US-08-714-741-44
5	71	12.9	1280	4	US-09-672-810-2
6	71	12.9	1283	4	US-09-672-810-4
7	70	12.7	365	4	US-09-252-991A-30166
8	69	12.5	491	4	US-09-248-796A-17049
9	69	12.5	1280	4	US-09-672-810-7
10	69	12.5	1280	4	US-09-672-725C-4
11	69	12.5	1280	4	US-10-044-671-2
12	69	12.5	1281	4	US-09-672-725C-2
13	69	12.5	1281	4	US-09-672-725C-23
14	69	12.5	1281	4	US-09-672-725C-25
15	69	12.5	1281	4	US-09-672-725C-27
16	68	12.3	1280	2	US-08-593-276-19
17	68	12.3	1280	2	US-08-752-447-2
18	68	12.3	1280	3	US-09-316-167-2
19	68	12.3	1280	4	US-09-767-594-2
20	68	12.3	1280	4	US-09-672-810-5
21	68	12.3	1280	4	US-09-397-233-2
22	68	12.3	1280	4	US-09-672-725C-7
23	68	12.3	1280	6	5206352-4
24	67.5	12.3	312	4	US-09-252-991A-19374
25	67.5	12.3	459	4	US-09-328-352-4648
26	67.5	12.3	902	1	US-08-701-846-2
27	66	12.0	115	4	US-09-252-991A-28403

28 65 11.8 730 4 US-09-107-532A-4752 Sequence 4752, Ap
29 64.5 11.7 139 4 US-09-252-991A-19245 Sequence 19245, A
30 64.5 11.7 486 4 US-08-622-191-7 Sequence 7, Appli
31 64 11.6 1576 4 US-09-562-702A-24 Sequence 24, Appl
32 64 11.6 1576 4 US-09-561-818A-24 Sequence 24, Appl
33 64 11.6 1584 4 US-09-562-702A-28 Sequence 28, Appl
34 64 11.6 1809 4 US-09-562-702A-22 Sequence 22, Appl
35 64 11.6 1809 4 US-09-561-818A-22 Sequence 22, Appl
36 64 11.6 1609 4 US-09-538-092-900 Sequence 900, App
37 64 11.6 1617 4 US-09-562-702A-26 Sequence 26, Appl
38 63.5 11.5 1019 1 US-08-296-014A-4 Sequence 4, Appli
39 63.5 11.5 1019 2 US-08-877-620-4 Sequence 4, Appli
40 63.5 11.5 1019 2 US-08-287-368-4 Sequence 4, Appli
41 63.5 11.5 1019 4 US-09-626-795-4 Sequence 4, Appli
42 63.5 11.5 1083 1 US-08-296-014A-2 Sequence 2, Appli
43 63.5 11.5 1083 2 US-08-596-405-2 Sequence 2, Appli
44 63.5 11.5 1083 2 US-08-877-620-2 Sequence 2, Appli

ALIGNMENTS

RESULT 1

US-08-169-613A-2
; Sequence 2, Application US/08169613A
; Patent No. 6486380
; GENERAL INFORMATION:
; APPLICANT: Epstein, Paul
; TITLE OF INVENTION: Pancreatic B Cell Hexokinase Transgene
; FILE REFERENCE: P0044US0
; CURRENT APPLICATION NUMBER: US/08/169,613A
; CURRENT FILING DATE: 1993-12-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 486
; TYPE: PRT
; ORGANISM: Yeast
US-08-169-613A-2

Query Match 13.7%; Score 75.5; DB 4; Length 486;

Best Local Similarity 30.2%; Pred. No. 1.7;

Matches 29; Conservative 9; Mismatches 27; Indels 31; Gaps 6;

QY 8 FSVITVM---LIAMASEMVGSAFTVMSGPCNNRABRYSKGCSAIHQKGYDFSYTG 64
DB 369 FGINIVQERKILRLSELIGA-----RAALSVCGIAICQKEGYK---TG 412
QY 65 QTAALYNQAGCGSVAHTRF-GSSARACNP-----FGW 95
DB 413 HIAA-----DGSVYNYRYPGFKEAANKADIYGW 441

RESULT 2

US-08-622-191-8
; Sequence 8, Application US/08622191A
; Patent No. 6632602
; GENERAL INFORMATION:
; APPLICANT: Jeang, Jen
; TITLE OF INVENTION: PLANT SUGAR SENSORS AND USES THEREOF
; FILE REFERENCE: 00786/307001
; CURRENT APPLICATION NUMBER: US/08/622,191A
; CURRENT FILING DATE: 1996-03-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 486
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-08-622-191-8

us-09-882-434a-1-rai

Mon Nov 8 15:44:32 2004

Query Match 13.7%; Score 75.5; DB 4; Length 486;
 Best Local Similarity 30.2%; Pred. No. 1.7;
 Matches 29; Conservative 9; Mismatches 27; Indels 31; Gaps 6;
 QY 8 FSVITVMM---LIAMSEVNGSAFTVWSPGNNRAERYSKGCSAIHQKGYDFSVTG 64
 DB 369 FGINTTVQERKLIRLSELIGA-----RAARLSVCGIAAICQKRGYK---TG 412
 QY 65 QTAALYNQACSGVAHTRP-GSSARACNP-----FGW 95
 DB 413 HIAA-----DGSVNRYPGFKEKAANKLKDYYG 441

RESULT 3
 US-07-872-678A-48
 ; Sequence 48; Application US/07872678A
 ; Patent No. 5541060
 ; GENERAL INFORMATION:
 ; APPLICANT: Bell, Graeme, et al.
 ; TITLE OF INVENTION: DETECTION OF EARLY-ONSET
 ; TITLE OF INVENTION: NON-INSULIN-DEPENDENT DIABETES MELLITUS
 ; NUMBER OF SEQUENCES: 48
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Arnold, White & Durkee
 ; STREET: Post Office Box 4433
 ; CITY: Houston
 ; STATE: Texas
 ; COUNTRY: USA
 ; ZIP: 77210
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent in Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/07/872,678A
 ; FILING DATE: 22-APRIL-1992
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Coughlin, Daniel F.
 ; REGISTRATION NUMBER: 36,111
 ; REFERENCE/DOCKET NUMBER: ARCD016
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 713-787-1400
 ; TELEFAX: 713-789-2679
 ; TELEX: 79-0924
 ; INFORMATION FOR SEQ ID NO: 48:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 486 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; US-07-872-678A-48

Query Match 13.5%; Score 74.5; DB 1; Length 486;
 Best Local Similarity 39.3%; Pred. No. 2.2;
 Matches 24; Conservative 4; Mismatches 18; Indels 15; Gaps 4;
 QY 40 RAERYSKGCSAIHQKGYDFSVTGTAALYNQACSGVAHTRP-GSSARACNP---FG 94
 DB 391 RAARLSVCGIAAICQKRGYK---TGHIAA-----DGSVSTRYPGFKEKAANKLKDYYG 440
 QY 95 W 95
 DB 441 W 441

RESULT 4
 US-08-714-741-44
 ; Sequence 44; Application US/08714741
 ; Patent No. 6500613
 ; GENERAL INFORMATION:

APPLICANT: Briles, David E.
 APPLICANT: McDaniel, Larry S.
 APPLICANT: Swiatlo, Edwin
 APPLICANT: Yother, Janet
 APPLICANT: Crain, Marilyn J.
 APPLICANT: Hollingshead, Susan
 APPLICANT: Tart, Rebecca
 APPLICANT: Brooks-Walter, Alexis
 TITLE OF INVENTION: PNEUMOCOCCAL GENES, PORTIONS THEREOF.
 TITLE OF INVENTION: EXPRESSION PRODUCTS THEREFROM, AND USES OF SUCH GENES,
 TITLE OF INVENTION: PORTIONS AND PRODUCTS
 NUMBER OF SEQUENCES: 47
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Curtis, Morris & Safford, P.C.
 STREET: 530 Fifth Avenue
 CITY: New York
 STATE: New York
 COUNTRY: U.S.
 ZIP: 10036
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/714,741
 FILING DATE: 16-SEP-1996
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Frommer Esq., William S.
 REGISTRATION NUMBER: 25,506
 REFERENCE/DOCKET NUMBER: 454312-2460
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 840-3333
 TELEFAX: (212) 840-0712
 INFORMATION FOR SEQ ID NO: 44:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 908 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 US-08-714-741-44

Query Match 13.5%; Score 74.5; DB 4; Length 908;
 Best Local Similarity 34.2%; Pred. No. 4.8;
 Matches 25; Conservative 6; Mismatches 39; Indels 3; Gaps 2;
 QY 18 AMASEVNGSAFTVWSPGNNRAERYSKGCSAIHQKGYDFSVTGTAALYNQACSG 77
 DB 240 AAACATTGAAATAATTAAGC--AAGCAAGCGAAGTTGAGACTGCTATAA-AAAGCTG 296
 QY 78 VAHTEFGSSARAC 90
 DB 297 AATTAGAAAAAAC 309

RESULT 5
 US-09-672-810-2
 ; Sequence 2; Application US/09672810
 ; Patent No. 6617450
 ; GENERAL INFORMATION:
 ; APPLICANT: STOCKER, PENNY J.
 ; APPLICANT: STEINEL-CRESPI, DOROTHY T.
 ; APPLICANT: CRESPI, CHARLES L.
 ; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
 ; FILE REFERENCE: G0307/7018
 ; CURRENT APPLICATION NUMBER: US/09/672,810
 ; CURRENT FILING DATE: 2000-09-28
 ; PRIOR APPLICATION NUMBER: US 60/156,921
 ; PRIOR FILING DATE: 1999-09-28
 ; PRIOR APPLICATION NUMBER: US 60/158,818
 ; PRIOR FILING DATE: 1999-10-12


```
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: Macaca fascicularis
US-09-672-810-2

Query Match      12.9%; Score 71; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 19;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVWMLIAVASEMV-----NGSAFTVWSGPGCNNAERYSKGCSAIHQKGYD 59
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
Db 334 VFFSVLIGAFSGQASPSIEAFANARGAAFEIKIIDNKPSIDSYSGHKKPDNIKGNLE 393
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
QY 60 -----FSY-----TGQTAALYNQAGC 75
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
Db 394 FRNVHFSYPSRKEVKILKGLNLKLVQSGQTVALVGNSGC 431

RESULT 6
US-09-672-810-4
; Sequence 4, Application US/09672810
; Patent No. 6617450
; GENERAL INFORMATION:
; APPLICANT: STOCKER, PENNY J.
; APPLICANT: STEINEL-CRESPI, DOROTHY T.
; APPLICANT: CRESPI, CHARLES L.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7018
; CURRENT APPLICATION NUMBER: US/09/672,810
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,921
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/158,818
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 1283
; TYPE: PRT
; ORGANISM: Macaca fascicularis
US-09-672-810-4

Query Match      12.9%; Score 71; DB 4; Length 1283;
Best Local Similarity 25.5%; Pred. No. 19;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVWMLIAVASEMV-----NGSAFTVWSGPGCNNAERYSKGCSAIHQKGYD 59
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
Db 337 VFFSVLIGAFSGQASPSIEAFANARGAAFEIKIIDNKPSIDSYSGHKKPDNIKGNLE 396
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
QY 60 -----FSY-----TGQTAALYNQAGC 75
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
Db 397 FRNVHFSYPSRKEVKILKGLNLKLVQSGQTVALVGNSGC 434

RESULT 7
US-09-252-991A-30166
; Sequence 30166, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
```

```
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 30166
; LENGTH: 365
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-30166

Query Match      12.7%; Score 70; DB 4; Length 365;
Best Local Similarity 27.8%; Pred. No. 5.2;
Matches 22; Conservative 7; Mismatches 46; Indels 4; Gaps 2;

QY 17 IAMSVMNGAFTVWSGPGCNNAERYSKGCSAIHQKGYDFSFTGTQTAALYNQAGCS 76
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
Db 166 LACAVDATSAVFAKPGFGGRCVCPALCGWEDTGTSGG---SSTGGAEETLAGSRACV 222
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
QY 77 GVA-HTRFGSSARACNPF 94
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
Db 223 DAATRAETAGACRATDPDG 241

RESULT 8
US-09-248-796A-17049
; Sequence 17049, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICA
; TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 17049
; LENGTH: 491
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-17049

Query Match      12.5%; Score 69; DB 4; Length 491;
Best Local Similarity 39.4%; Pred. No. 9.8;
Matches 13; Conservative 8; Mismatches 12; Indels 0; Gaps 0;

QY 40 RAERYSKGCSAIHQKGYDFSFTGTQTAALYNQ 72
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:
Db 398 RSARFSVCGIAALCQKRGYKTAHCADGSVYNK 430
      :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||: :|||:

RESULT 9
US-09-672-810-7
; Sequence 7, Application US/09672810
; Patent No. 6617450
; GENERAL INFORMATION:
; APPLICANT: STOCKER, PENNY J.
; APPLICANT: STEINEL-CRESPI, DOROTHY T.
; APPLICANT: CRESPI, CHARLES L.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7018
; CURRENT APPLICATION NUMBER: US/09/672,810
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,921
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/158,818
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: Canis familiaris
```

```
US-09-672-810-7
Query Match      12.5%; Score 69; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAPTVMSGPGCNCNRAERYSKCGCSAIHQKGYD 59
DB 335 VFFSVLIGAFSIGQASPSIEAFANARGAAVEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 394
QY 60 -----FSY-----TGQTAALYNQAGC 75
DB 395 FKNVHFSYPSRKEVKILKGLNLKVLKQSGQTVALVGNSSC 432

RESULT 10
US-09-672-725C-4
; Sequence 4, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-725C-4

Query Match      12.5%; Score 69; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAPTVMSGPGCNCNRAERYSKCGCSAIHQKGYD 59
DB 335 VFFSVLIGAFSIGQASPSIEAFANARGAAVEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 394
QY 60 -----FSY-----TGQTAALYNQAGC 75
DB 395 FKNVHFSYPSRKEVKILKGLNLKVLKQSGQTVALVGNSSC 432

RESULT 11
US-10-044-671-2
; Sequence 2, Application US/10044671
; Patent No. 6790621
; GENERAL INFORMATION:
; APPLICANT: Washington State University Research Foundation
; APPLICANT: Mealey, Katrina
; APPLICANT: Bentjen, Steven
; TITLE OF INVENTION: MDRI VARIANTS AND METHODS FOR THEIR USE
; FILE REFERENCE: 4630-61733
; CURRENT APPLICATION NUMBER: US/10/044,671
; CURRENT FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/261,578
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: US 60/314,829
; PRIOR FILING DATE: 2001-08-24
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 1280
; TYPE: PRT
US-10-044-671-2

; ORGANISM: Canis familiaris
US-10-044-671-2

Query Match      12.5%; Score 69; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAPTVMSGPGCNCNRAERYSKCGCSAIHQKGYD 59
DB 336 VFFSVLIGAFSIGQASPSIEAFANARGAAVEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 395
QY 60 -----FSY-----TGQTAALYNQAGC 75
DB 396 FKNVHFSYPSRKEVKILKGLNLKVLKQSGQTVALVGNSSC 433

RESULT 12
US-09-672-725C-2
; Sequence 2, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 1281
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-725C-2

Query Match      12.5%; Score 69; DB 4; Length 1281;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAPTVMSGPGCNCNRAERYSKCGCSAIHQKGYD 59
DB 336 VFFSVLIGAFSIGQASPSIEAFANARGAAVEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 395
QY 60 -----FSY-----TGQTAALYNQAGC 75
DB 396 FKNVHFSYPSRKEVKILKGLNLKVLKQSGQTVALVGNSSC 433

RESULT 13
US-09-672-725C-23
; Sequence 23, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 23
; LENGTH: 1281
US-09-672-725C-23
```

```
; LENGTH: 1281
; TYPE: PRT
; ORGANISM: Canis familiaris
US-0672-725C-27

Query Match          12.5%; Score 69; DB 4; Length 1281;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3

Qy      6 LFSSVITVMIIAMASEMV-----NGSAFTVMGPGCNRAERYSKSCSALHOKGGYD 59
        :|||::|         ||:::   ::|||::|       :|||::|
Db     336 VFVSVLIGAFSIGQSPIEFANARGAAVEIFKIIDNKPSIDSYKSGHGKPDNIKNLE 395

           :|||::|
Qy    60 -----FSY-----TCQTAALYNQAGC 75
           :|||::|
Db   396 FKNHFVSYPSPKEVKILGNLKVQQSQTTVALVGNCGC 433
```

Search completed: November 5, 2004, 21:56:30
Job time : 45 secs

```
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-72SC-23

      Query Match          12.5% ; Score 69 ; DB 4 ; Length 1281;
      Best Local Similarity   25.5% ; Pred. No. 32;
      Matches       25; Conservative    12; Mismatches     33; Indels      28; Gaps        3
```

3

```
QY           6 LPFSVITVMILIAASEMV-----NGSAFTWMSGPGCCNNRARYSKQCQSALHKGGYD 59
            :|||:         |             : |||:         |:              :
Db          336 VFVSVLICAFSIGAQSPSIEAFAFARGAAVEIPKIIDNKPSIDSYSKSCHKPDNIKGNLE 395
                        :|||:         |             : |||:         |:              :
```

TGTATLYNQACG 75
||||
||||

```
QY           60 -----FSY-----TCGTATLYNQACG 75
                |||
                |||
```

FCNWHFYSPSRKEVKILKGLNLKVCSQTVALGVNSGC 433

```
Dbl           396 FCNWHFYSPSRKEVKILKGLNLKVCSQTVALGVNSGC 433
```

```

RESULT 14
US-09-672-725C-25
; Sequence 25, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steinel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND US
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 66/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 1281
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-725C-25

```

```

Query Match      12.5%; Score 69; DB 4; Length 1281;
Best Local Similarity 25.5%; Pred.No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY      6 LFPSVITVMVLIAFASRMV-----NGSAFTVMSGPGCNNAERYSKSCSIAHKGGYD 59
        ||||| : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db      336 VFPSVLGAFGIGQASPSEAFANARGAAYEIKIINDKPSIDSYSGSKGHPDNKGKLE 395
        ||||| : | : | : | : | : | : | : | : | : | : | : | : | : | : |

QY      60 -----FSY-----TGOTAAALYNQAQC 75
        ||||| : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db      395 FKNVHFSYPSRKEVKILKGLNKVCSGOTVALVNSGC 433
        ||||| : | : | : | : | : | : | : | : | : | : | : | : | : | : |

```

```

RESULT 15
US-09-672-725C-27
; Sequence 27, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 27

```

